WO2005007838A1 - 細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株 - Google Patents
細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株Info
- Publication number
- WO2005007838A1 WO2005007838A1 PCT/JP2004/009379 JP2004009379W WO2005007838A1 WO 2005007838 A1 WO2005007838 A1 WO 2005007838A1 JP 2004009379 W JP2004009379 W JP 2004009379W WO 2005007838 A1 WO2005007838 A1 WO 2005007838A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- hydrogen atom
- compound
- lower alkyl
- cells
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 339
- 239000003112 inhibitor Substances 0.000 title claims abstract description 148
- 239000001963 growth medium Substances 0.000 title claims abstract description 13
- 238000009630 liquid culture Methods 0.000 title abstract 3
- 238000004113 cell culture Methods 0.000 title description 34
- 210000004748 cultured cell Anatomy 0.000 title description 5
- 210000000130 stem cell Anatomy 0.000 claims abstract description 121
- 230000004069 differentiation Effects 0.000 claims abstract description 110
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 83
- 230000024245 cell differentiation Effects 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 71
- 238000012258 culturing Methods 0.000 claims abstract description 25
- 150000003384 small molecules Chemical class 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims description 202
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 154
- 125000000217 alkyl group Chemical group 0.000 claims description 117
- -1 hydroxycarbonyl group Chemical group 0.000 claims description 116
- 239000002609 medium Substances 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 57
- 125000003545 alkoxy group Chemical group 0.000 claims description 56
- 125000002252 acyl group Chemical group 0.000 claims description 49
- 230000014509 gene expression Effects 0.000 claims description 49
- 125000005843 halogen group Chemical group 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 44
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 40
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 30
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 28
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 26
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 125000004429 atom Chemical group 0.000 claims description 21
- 101150012532 NANOG gene Proteins 0.000 claims description 18
- 125000004122 cyclic group Chemical group 0.000 claims description 18
- 125000002560 nitrile group Chemical group 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 16
- 238000002054 transplantation Methods 0.000 claims description 16
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 15
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 14
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 239000000651 prodrug Substances 0.000 claims description 11
- 229940002612 prodrug Drugs 0.000 claims description 11
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 10
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 10
- 230000009471 action Effects 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 6
- 229940113088 dimethylacetamide Drugs 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 125000005181 hydroxyalkylaminoalkyl group Chemical group 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 4
- QNBJDLSBBZVXNW-UHFFFAOYSA-N C1=CC(C(=O)C)=CC=C1N=NC(C(O)=O)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound C1=CC(C(=O)C)=CC=C1N=NC(C(O)=O)=C1C2=CC=CC=C2CC(C)(C)N1 QNBJDLSBBZVXNW-UHFFFAOYSA-N 0.000 claims description 4
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000005245 nitryl group Chemical group [N+](=O)([O-])* 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000000816 ethylene group Chemical class [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000012136 culture method Methods 0.000 abstract description 13
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 abstract 4
- 239000000243 solution Substances 0.000 description 81
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 62
- 239000000203 mixture Substances 0.000 description 46
- 235000002639 sodium chloride Nutrition 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 241000699666 Mus <mouse, genus> Species 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 35
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 30
- 239000002904 solvent Substances 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 239000000126 substance Substances 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 21
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 21
- 108010010803 Gelatin Proteins 0.000 description 20
- 229920000159 gelatin Polymers 0.000 description 20
- 235000019322 gelatine Nutrition 0.000 description 20
- 235000011852 gelatine desserts Nutrition 0.000 description 20
- 239000008273 gelatin Substances 0.000 description 19
- 101150033839 4 gene Proteins 0.000 description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 239000007795 chemical reaction product Substances 0.000 description 17
- 239000012981 Hank's balanced salt solution Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 210000003014 totipotent stem cell Anatomy 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000006143 cell culture medium Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 241000282567 Macaca fascicularis Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 241000282693 Cercopithecidae Species 0.000 description 9
- 241000288906 Primates Species 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- 230000002411 adverse Effects 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 229910002091 carbon monoxide Inorganic materials 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- ZXSRRUROLCGTBS-UHFFFAOYSA-N C1=CC(C(=O)C)=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound C1=CC(C(=O)C)=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 ZXSRRUROLCGTBS-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 239000012954 diazonium Substances 0.000 description 6
- 150000001989 diazonium salts Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 108010082117 matrigel Proteins 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000010288 sodium nitrite Nutrition 0.000 description 5
- 229920001059 synthetic polymer Polymers 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical class OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 210000001654 germ layer Anatomy 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- LCYIZBVMHJGJGP-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone;hydrochloride Chemical compound Cl.CC(=O)C1=CC=C(N)C=C1 LCYIZBVMHJGJGP-UHFFFAOYSA-N 0.000 description 3
- AHZPICXQLBUYKV-UHFFFAOYSA-N 2-phenyldiazenylacetamide Chemical class NC(=O)CN=NC1=CC=CC=C1 AHZPICXQLBUYKV-UHFFFAOYSA-N 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- SAQUSDSPQYQNBG-UHFFFAOYSA-N chembl355496 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC(Br)=CC=C21 SAQUSDSPQYQNBG-UHFFFAOYSA-N 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LVDRQRPNKHMEME-UHFFFAOYSA-N 2-(2-acetyl-3,3-dimethyl-4h-isoquinolin-1-ylidene)-2-[(4-acetylphenyl)diazenyl]acetamide Chemical compound C12=CC=CC=C2CC(C)(C)N(C(=O)C)C1=C(C(N)=O)N=NC1=CC=C(C(C)=O)C=C1 LVDRQRPNKHMEME-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- JIEINYQEXWLMCU-UHFFFAOYSA-N 7-bromo-3-hydroxy-n-(2-methoxyphenyl)naphthalene-2-carboxamide Chemical compound COC1=CC=CC=C1NC(=O)C1=CC2=CC(Br)=CC=C2C=C1O JIEINYQEXWLMCU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 108091028026 C-DNA Proteins 0.000 description 2
- UTJDLLNFLCWVPU-UHFFFAOYSA-N C1=CC(C(=O)C)=CC=C1N=NC(C(=O)NC=1C=CC=CC=1)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound C1=CC(C(=O)C)=CC=C1N=NC(C(=O)NC=1C=CC=CC=1)=C1C2=CC=CC=C2CC(C)(C)N1 UTJDLLNFLCWVPU-UHFFFAOYSA-N 0.000 description 2
- HKJVWUIGFHYUNC-UHFFFAOYSA-N CC1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 Chemical compound CC1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 HKJVWUIGFHYUNC-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- JAFORNOMBFOBFV-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(=O)NC)N=NC1=CC=C(C(C)=O)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(=O)NC)N=NC1=CC=C(C(C)=O)C=C1 JAFORNOMBFOBFV-UHFFFAOYSA-N 0.000 description 2
- 101150098334 NOG gene Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000011880 melting curve analysis Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- NFHRNKANAAGQOH-UHFFFAOYSA-N triphenylstannane Chemical compound C1=CC=CC=C1[SnH](C=1C=CC=CC=1)C1=CC=CC=C1 NFHRNKANAAGQOH-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 1
- GPRYKVSEZCQIHD-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone Chemical compound CC(=O)C1=CC=C(N)C=C1 GPRYKVSEZCQIHD-UHFFFAOYSA-N 0.000 description 1
- VVZNWYXIOADGSW-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-methyl-3-nitroindol-6-ol Chemical compound C1=CC(OC)=CC=C1N1C2=CC(O)=CC=C2C([N+]([O-])=O)=C1C VVZNWYXIOADGSW-UHFFFAOYSA-N 0.000 description 1
- ZCKPBWGFIZYWRR-UHFFFAOYSA-N 1-[3-(1H-pyrrol-2-yl)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2NC=CC=2)=C1 ZCKPBWGFIZYWRR-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XAWPKHNOFIWWNZ-UHFFFAOYSA-N 1h-indol-6-ol Chemical compound OC1=CC=C2C=CNC2=C1 XAWPKHNOFIWWNZ-UHFFFAOYSA-N 0.000 description 1
- OWEFQTXQEHYDEJ-UHFFFAOYSA-N 2,3-dihydroxypropanal diphosphono hydrogen phosphate Chemical compound OCC(O)C=O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O OWEFQTXQEHYDEJ-UHFFFAOYSA-N 0.000 description 1
- VEQRBCZWJQYGOS-UHFFFAOYSA-N 2-[(4-acetylphenyl)diazenyl]-2-(2,3,3-trimethyl-4h-isoquinolin-1-ylidene)acetamide Chemical compound C12=CC=CC=C2CC(C)(C)N(C)C1=C(C(N)=O)N=NC1=CC=C(C(C)=O)C=C1 VEQRBCZWJQYGOS-UHFFFAOYSA-N 0.000 description 1
- WQFHCZGUBRVAAW-UHFFFAOYSA-N 2-[(4-acetylphenyl)diazenyl]-2-(3,3-dimethyl-2,4-dihydro-1h-isoquinolin-1-yl)acetamide Chemical compound C1=CC(C(=O)C)=CC=C1N=NC(C(N)=O)C1C2=CC=CC=C2CC(C)(C)N1 WQFHCZGUBRVAAW-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- GOKJYAGJIKHEPU-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(2,4-dimethylphenyl)acetamide Chemical compound CC1=CC(C)=CC=C1NC(=O)C(C#N)=C1C2=CC=CC=C2CC(C)(C)N1 GOKJYAGJIKHEPU-UHFFFAOYSA-N 0.000 description 1
- GLMLPMCMLPZXIH-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(2-methylphenyl)acetamide Chemical compound CC1=CC=CC=C1NC(=O)C(C#N)=C1C2=CC=CC=C2CC(C)(C)N1 GLMLPMCMLPZXIH-UHFFFAOYSA-N 0.000 description 1
- FIVBUKNDIHKWOJ-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)C(C#N)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 FIVBUKNDIHKWOJ-UHFFFAOYSA-N 0.000 description 1
- ZDOBASAMTAMXFX-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C(C#N)=C1C2=CC=CC=C2CC(C)(C)N1 ZDOBASAMTAMXFX-UHFFFAOYSA-N 0.000 description 1
- IHAMKSSHLSNUIB-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-phenylacetamide Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C#N)C(=O)NC1=CC=CC=C1 IHAMKSSHLSNUIB-UHFFFAOYSA-N 0.000 description 1
- DGJMPUGMZIKDRO-NJFSPNSNSA-N 2-cyanoacetamide Chemical class NC(=O)[14CH2]C#N DGJMPUGMZIKDRO-NJFSPNSNSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- RIWRBSMFKVOJMN-UHFFFAOYSA-N 2-methyl-1-phenylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=CC=C1 RIWRBSMFKVOJMN-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- CKQHAYFOPRIUOM-UHFFFAOYSA-N 3'-Aminoacetophenone Chemical compound CC(=O)C1=CC=CC(N)=C1 CKQHAYFOPRIUOM-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical group CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- SARKXLKWFKNUMR-UHFFFAOYSA-N 4-benzamido-5-chloro-2-methylbenzenediazonium;chloride Chemical compound [Cl-].C1=C([N+]#N)C(C)=CC(NC(=O)C=2C=CC=CC=2)=C1Cl SARKXLKWFKNUMR-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- DEFLNOSTNCSZRB-IDTAVKCVSA-N 9-[(2r,3r,4r,5r)-3,4-dimethoxy-5-(methoxymethyl)oxolan-2-yl]-n-methoxypurin-6-amine Chemical compound CO[C@@H]1[C@H](OC)[C@@H](COC)O[C@H]1N1C2=NC=NC(NOC)=C2N=C1 DEFLNOSTNCSZRB-IDTAVKCVSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- ZBJJDYGJCNTNTH-UHFFFAOYSA-N Betahistine mesilate Chemical group CS(O)(=O)=O.CS(O)(=O)=O.CNCCC1=CC=CC=N1 ZBJJDYGJCNTNTH-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- YMOUMBLAHTXJKV-UHFFFAOYSA-N C1=CC(OC)=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound C1=CC(OC)=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 YMOUMBLAHTXJKV-UHFFFAOYSA-N 0.000 description 1
- HYZCNQMKWKNVCF-UHFFFAOYSA-N CC(=O)C1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 Chemical compound CC(=O)C1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 HYZCNQMKWKNVCF-UHFFFAOYSA-N 0.000 description 1
- QRVXDQNZYITBPH-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound CC(=O)C1=CC=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 QRVXDQNZYITBPH-UHFFFAOYSA-N 0.000 description 1
- XPBPXOCYYOHHLJ-UHFFFAOYSA-N CC(=O)NC1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 Chemical compound CC(=O)NC1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 XPBPXOCYYOHHLJ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010010996 Corneal degeneration Diseases 0.000 description 1
- 206010061788 Corneal infection Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 description 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 101000942966 Mus musculus Leukemia inhibitory factor Proteins 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 1
- JLCLSIGDGYWAKQ-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(=O)N(C)C)N=NC1=CC=C(C(C)=O)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(=O)N(C)C)N=NC1=CC=C(C(C)=O)C=C1 JLCLSIGDGYWAKQ-UHFFFAOYSA-N 0.000 description 1
- BNBOUMIJPUPSKC-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(Br)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(Br)C=C1 BNBOUMIJPUPSKC-UHFFFAOYSA-N 0.000 description 1
- ICSKFBZOZMUFRY-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(Cl)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(Cl)C=C1 ICSKFBZOZMUFRY-UHFFFAOYSA-N 0.000 description 1
- MWJAJPFUSWPTEN-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(S(N)(=O)=O)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(S(N)(=O)=O)C=C1 MWJAJPFUSWPTEN-UHFFFAOYSA-N 0.000 description 1
- IDQAJIUSPXWBBJ-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C([N+]([O-])=O)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C([N+]([O-])=O)C=C1 IDQAJIUSPXWBBJ-UHFFFAOYSA-N 0.000 description 1
- IHVDURBVOODYKG-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC(Br)=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC(Br)=C1 IHVDURBVOODYKG-UHFFFAOYSA-N 0.000 description 1
- BSRJGMWXNNJOBZ-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC(S(N)(=O)=O)=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC(S(N)(=O)=O)=C1 BSRJGMWXNNJOBZ-UHFFFAOYSA-N 0.000 description 1
- NAKGPWBQCDCQLN-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC([N+]([O-])=O)=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC([N+]([O-])=O)=C1 NAKGPWBQCDCQLN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229920001007 Nylon 4 Polymers 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102400001107 Secretory component Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 244000047670 Viola x wittrockiana Species 0.000 description 1
- 235000004031 Viola x wittrockiana Nutrition 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 108091060592 XDNA Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- QDPOOGQUCJJZAO-FCXRPNKRSA-N [(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QDPOOGQUCJJZAO-FCXRPNKRSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000005075 adamantyloxy group Chemical group C12(CC3CC(CC(C1)C3)C2)O* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000008531 maintenance mechanism Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 238000006063 methoxycarbonylation reaction Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000010529 odontogenesis of dentin-containing tooth Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- FWMUJAIKEJWSSY-UHFFFAOYSA-N sulfur dichloride Chemical compound ClSCl FWMUJAIKEJWSSY-UHFFFAOYSA-N 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Definitions
- the present invention relates to a stem cell differentiation inhibitor comprising a low molecular compound, particularly a tetrahydroisoquinoline derivative as an active ingredient, a stem cell culture method using the same, a culture solution, and a stem cell line prepared using the same.
- the present invention further relates to a novel bicyclic compound having an effect of maintaining undifferentiation of stem cells.
- Organs and tissues damaged by trauma, illness, or even aging need to promote regeneration and restore their functions.
- real organs such as the heart, liver, kidney, and spleen are indispensable for life support, and their functions are impaired.Abolition is directly linked to death, so transplant medical treatments that seek to save lives by organ transplantation are being actively conducted. .
- the constant shortage of donors requires a new approach to address them.
- stem cells which are present in embryos or adults, and are thought to have the ability to divide indefinitely and differentiate in one or more directions, to produce tissues and organs, and to supplement defective tissues.
- Regenerative medicine is gaining attention as a treatment that surpasses the shortcomings of conventional organ transplantation.
- stem cells after stem cells are proliferated, they are differentiated and used for cell transplantation, or artificial tissues are constructed in conjunction with the use of artificial support tissues, and then transplanted into a living body or used as an artificial organ. Things are considered. If stem cells can be used for cell transplantation therapy and tissue engineering, it is expected that problems associated with conventional transplantation treatments, including autologous transplantation, such as tissue loss and donor shortage after transplantation of donors will be solved.
- Stem cells have been identified in many fields, such as blood vessels, nerves, blood, cartilage, bone, liver, and pancreas, and among them, totipotent stem cells, which have the ability to differentiate into all cell types, In addition to the regenerative medicine field mentioned above, cells for drug discovery and gene therapy In addition, the cells are particularly attracting attention as cells that can easily provide tissues.
- ES cells embryonic stem (Embryonic Stem, hereinafter ES) cells and embryonic germ (Embryonic Germ, hereafter EG) cells are known.
- ES cells are a cell line isolated from the inner cell mass (ICM) of the mouse blastocyst stage (Evans et al., Nature, 292, pl54, 1981).
- the cells that make up an individual are derived from the inner cell mass (ICM) at the blastocyst stage or the primary ectoderm derived from the epiblast of the gastrulation (epiblast).
- Epiblast is a totipotent stem cell group.
- ES cells retain their ability to differentiate into various tissue-forming tissues and have the ability to differentiate into all mature adult cells by forming normal and chimeric embryos. It also has the ability to generate various cells, such as blood cells, cardiomyocytes, vascular endothelial cells, nerve cells, pigment cells, and endocrine cells, depending on the conditions of in vitro differentiation induction. Medicine, p 81-89, 2000).
- EG cells are cells established by culturing primordial germ cells in the presence of LIF (leukemia inhibitory factor) and bFGF (basic fibroblast growth factor) (Matsui et al., Cell, 7). 0, p841, 1992, Resnic et al., Nature, 359, p550, 1992), has the ability to differentiate into various tissues like ES cells ing.
- LIF leukemia inhibitory factor
- bFGF basic fibroblast growth factor
- ES cell lines other than mice have pluripotency similarly to mouse ES cells
- Porcine ES cells Strojek et al., Theriogenology, 33: p901, 1990
- Sheep ES cells Handyside, Roux's Arch. Dev. Biol., 196: pl85, 1987
- Hamster ES cells Doetschman et al., Dev. Biol., 127, p224, 1988
- germ monkey ES cells Thomson et al., Proc. Natl. Acad. Sci.
- marmoset ES cells Thomson et al., Biology of Production, 55, p254, 1996
- human ES cells Thomson et al., Science, 282, pll45, 1998
- Reubinoff et al. (Nature Biotech, 18, p399, 2000
- R. cynomolgus monkey ES cells Suemori et al., Dev. Dyn. 222, P273, 2001).
- LIF leukemia inhibitory factor
- PD 98059 (manufactured by Cell Signaling Technology) has been reported as a low-molecular compound that amplifies LIF-induced undifferentiation of embryonic stem cells, but the effect of PD 98059 is LIF-dependent. There is no effect by itself (Burdon et al., Dev. Biol., 210, p30, 1999), so the above-mentioned problems cannot be solved.
- the differentiation inhibitor of the present invention contains a low-molecular compound as an active ingredient, but it has not been known that the low-molecular compound maintains an undifferentiated state of totipotent stem cells. Therefore, the low molecular weight compounds represented by the general formulas (1) to (10) described in the present specification did not have any known effects of maintaining the undifferentiation of totipotent stem cells.
- the present invention has been made in order to achieve the above object, and is a differentiation inhibitor capable of culturing stem cells and embryonic stem cells in an undifferentiated state.
- the present invention relates to a method, a cell culture solution containing such a differentiation inhibitor, and a cell line produced by culturing using such a differentiation inhibitor.
- the present invention has the following configuration.
- a stem cell differentiation inhibitor comprising a low molecular compound or a salt thereof as an active ingredient.
- RRR 3 and R 4 may be the same or different and each represents an electron-withdrawing group, an electron-donating group, or a hydrogen atom.
- Ring A represents a 5- to 8-membered ring containing at least one heteroatom in the ring.
- X represents an alkylene group having 0 to 10 main chain atoms.
- An alkylene group having 0 atoms represents a single bond.
- the bond bonded to ring A may be a group that forms a double bond.
- the alkylene group has an electron absorbing property as a substituent.
- G represents an electron withdrawing group, an electron donating group or an aromatic group which may have a hydrogen atom.
- the ring A may have one or more electron-withdrawing groups and / or electron-donating groups as substituents other than the XG group.
- the stem cell differentiation inhibitor according to the above (1) which is a compound represented by the formula:
- a ring is a 5- or 6-membered ring containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom. Agent.
- the alkylene group represented by X is an alkyl group, an acyl group, an alkoxy group, a nitro group, a hydroxycarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, a nitrile group and a halogen atom
- R 5 , R 6 , R 7 , R 8 , and R 9 may be the same or different, and represent an electron-withdrawing group, an electron-donating group, or a hydrogen atom.
- the stem cell differentiation inhibitor according to the above (2) which is a compound represented by the formula:
- the low molecular weight compound is represented by the general formula (3)
- R 5 and R 6 may be the same or different and each represents an electron-withdrawing group, an electron-donating group, or a hydrogen atom.
- the stem cell differentiation inhibitor according to the above (2) which is a compound represented by the formula:
- R 1 R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are the same as defined in the above (6).
- R 1Q , R 11 R 12 and R 13 may be the same or different and each represents an electron withdrawing group, an electron donating group or a hydrogen atom.
- a double-sided broken line represents a single bond or a double bond. If the double dashed line represents a double bond, geometric isomers exist for the wavy line. The arrangement of these geometric isomers is not particularly limited, and may be independently E-form or Z-form. ]
- the agent for suppressing stem cell differentiation according to the above (6) which is a compound represented by the formula:
- R ⁇ R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R ", R 12 , and R 13 are each independently A group or atom selected from the group consisting of an alkyl group, an acyl group, an alkoxy group, a nitro group, a hydroxycarbonyl group, a nitrile group, an alkoxycarbonyl group, an aminocarbonyl group, a halogen atom and a hydrogen atom.
- the agent for suppressing stem cell differentiation according to (8).
- the low molecular weight compound has the general formula (5)
- R 1Q , 1 and R 12 may be the same or different and each represents an electron withdrawing group, an electron donating group or a hydrogen atom.
- the stem cell differentiation inhibitor according to the above (6) which is a compound represented by the formula:
- R ⁇ R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 1 and R 12 are each independently an alkyl group, an acyl group
- the above (10) which is a group or atom selected from the group consisting of a group, an alkoxy group, a nitro group, a hydroxycarbonyl group, a nitrile group, an alkoxycarbonyl group, an aminocarbonyl group, a halogen atom and a hydrogen atom.
- Stem cell differentiation inhibitor is a group or atom selected from the group consisting of a group, an alkoxy group, a nitro group, a hydroxycarbonyl group, a nitrile group, an alkoxycarbonyl group, an aminocarbonyl group, a halogen atom and a hydrogen atom.
- the low molecular weight compound is represented by the general formula (6)
- RR 2 , R 3 , R 4 , R 5 , and R 6 are the same as defined in the above (7).
- R 7 , R 8 and R 9 may be the same or different and each represents an electron withdrawing group, an electron donating group or a hydrogen atom.
- the stem cell differentiation inhibitor according to the above (7) which is a compound represented by the formula:
- R ⁇ R 2 S R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 each independently represent an alkyl group, an alkoxy group, a hydroxy group, a nitro group, a nitrile.
- RR 2 , R ⁇ R 4 , R 8 , R 9 and R 1 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group
- R 6 and R 7 is a lower alkyl group which may be the same or different
- R 11 is a hydrogen atom, a halogen atom, a nitro group or a lower alkoxy group
- R 12 is a hydrogen atom, a lower alkyl group
- R 13 is a hydroxycarbonyl group, a nitryl group, an aminocarbonyl group, or a lower alkoxycarbonyl group, wherein R 13 is a lower acyl group or a lower alkoxy group;
- the agent for suppressing stem cell differentiation according to (8).
- R ⁇ R 2 , R 3 , RR 8 , and R 9 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group, or a lower alkyl group
- d is a hydrogen atom, a halogen atom, a nitro group, a lower alkoxy group, or a lower alkoxycarbonyl group
- R 12 is a hydrogen atom, a lower alkyl group, a lower acyl group, or Is a lower alkoxy group
- R 1 and R 2 are hydrogen atoms
- R 3 is a hydroxyl group or an acetyloxy group
- R 4 is an acetyloxyalkyl group, a cyclic alkylaminoalkyl group which may contain an oxygen atom
- R 5 is a lower alkyl group or an arylaminovinyl group
- R 6 is a nitro group
- R 7 , R 8 , and R 9 are a hydroxyalkylaminoalkyl group or a hydrogen atom
- RR ⁇ R and R 4 may be the same or different and each is a hydrogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, or a halogen atom, and R 5 is a hydrogen atom, a lower acyl group.
- R 6 ⁇ Pi R 7 may each be the same or different, a hydrogen atom, a lower alkyl group or a lower alkyl group which may form a cyclic structure
- R 8 And R 9 are hydrogen atoms
- R 1 G , R 11 and R 12 may be the same or different, and each may be a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or A lower alkoxy group, wherein R 13 represents a hydroxycarbonyl group, a lower alkoxycarbonyl group, a secondary aminocarbonyl group or a tertiary aminocarbonyl group;
- Geometrical isomers exist in the wavy line portion, and the arrangement of these geometrical isomers is not particularly limited, and each may be independently an E-form or a Z-form.
- R 1 R 2 , R ⁇ and R 4 may be the same or different; An atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, or a halogen atom; R 5 is a hydrogen atom, a lower acyl group, or a lower alkyl group; R 6 and R 7 are the same or different; A hydrogen atom, a lower alkyl group or a lower alkyl group which may form a cyclic structure, R 8 and R 9 are hydrogen atoms, and R 1 G and R 12 are a hydrogen atom, a halogen atom, A nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group, R 11 is a lower acyl group, and R 13 is a hydroxycarbonyl group, a lower alkoxycarbonyl group, or an aminocarbonyl group .
- R 13 is a hydroxycarbonyl group, a lower alkoxycarbonyl group, or
- RR 2 , and R 4 may be the same or different and each is a hydrogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, or a halogen atom
- R 5 is a lower acryl group
- R 6 and R 7 may be the same or different, and each may be a hydrogen atom, a lower alkyl group or a lower alkyl group which may form a cyclic structure
- R 8 and R 9 is a hydrogen atom
- R 1 G, R 1 1 and R 1 2 are each may be the same or different, a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower Ashiru group or a lower alkoxy group
- R 13 represents a hydroxycarbonyl group, a lower alkoxycarbonyl group or an aminocarbonyl group.
- Geometric isomers exist in the wavy line portion, and the arrangement of these geometric isomers is not particularly limited, and
- R 2 , R 3 , and R 4 may be the same or different, and each is a hydrogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, or a halogen atom, and R 5 is a hydrogen atom.
- R 6 and R 7, which may be the same or different, may be a lower alkyl group or a lower alkyl group which may form a cyclic structure
- R 8 and R 9 is a hydrogen atom
- R 1 G , R 1 ⁇ and R 12 may be the same or different, and each represents a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group, or a lower alkoxy group.
- R 13 represents a nitrile group.
- geometrical isomers with respect to the wavy portion and the arrangement of these geometrical isomers is not particularly limited, and each may be independently the E-form or the Z-form. ]
- RR ⁇ R and R 4 may be the same or different and each is a hydrogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, or a halogen atom, and R 5 is a hydrogen atom, a lower acyl group.
- R 6 and R 7 may be the same or different and may form a hydrogen atom, a lower alkyl group or a cyclic structure, a lower alkyl group, 8 and R 9 are hydrogen atoms, and R 10 , R 11 , and R 12 may be the same or different, and each may be a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group, or a lower alkoxy group.
- R 13 represents a hydroxycarbyl group, a lower alkoxycarbonyl group, an aminocarbonyl group, or a nitrile group.
- R ⁇ R 2 , R 'and R 4 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group
- R 6 and R 7 are the same or different.
- R 8 , R 9 and R 1 G are hydrogen atoms. ?
- RRR 3 and R 4 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group
- R 6 and R 7 may be the same or different and may be lower.
- An alkyl group, R 8 , R 9 and R 1 D are hydrogen atoms
- R 11 is a lower acetyl group
- R 12 is a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acryl group, or A lower alkoxy group
- R 13 is a hydroxycarbyl group, a lower alkoxycarbonyl group, a carbamoyl group, a mono-lower alkylaminocarbonyl group, a di-lower alkylaminocarbonyl group, or a phenylaminocarbonyl group
- R ⁇ R 2 , R 3 , and R 4 are hydrogen atoms
- R 5 is a lower acyl group or a lower alkyl group
- R 6 and R 7 are the same but different
- R 8 , R 9 and R 1 Q are hydrogen atoms; ? Thank you!
- ⁇ May be the same or different, and each represents a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group, and R 13 is a hydroxycarbonyl group, a lower alkoxycarbonyl group,
- R ⁇ RR and R 4 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group
- R 6 and R 7 may be the same or different It is a lower alkyl group
- R 8 , R 9 and R 1 D are hydrogen atoms.
- ⁇ may be the same or different, and each represents a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group
- R 13 is a nitrile group
- R ⁇ RR and R 4 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group
- R 6 and R 7 may be the same or different
- R 8 , R 9 and R 1 Q are hydrogen atoms; ? as well as! ? ⁇ May be the same or different, and each represents a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group
- R 13 is a hydroxycarbonyl group or a lower alkoxycarbonyl group.
- (21) The compound according to (21) or a salt thereof, which is a canolebamoyl group, a mono-lower alkylaminocarbonyl group, a di-lower alkylaminocarbonyl group, a phenylaminocarbonyl group, or a nitrile group.
- An agent for inhibiting stem cell differentiation comprising the compound according to any one of (17) to (31) or a salt thereof as an active ingredient.
- Stem cells characterized by culturing stem cells in an undifferentiated state using the stem cell differentiation inhibitor according to any one of (1) to (16) and (32) to (38). Culture method.
- a pharmaceutical composition comprising the compound according to any of (17) to (31) or a salt thereof or a prodrug thereof.
- FIG. 1 shows the structure of Compound A of the present invention.
- Compound A is a compound in which R 1 to R 12 in formula (5) in FIG. 1 are represented by the groups or elements shown in the following table.
- FIG. 2 shows the structures of compounds BF of the present invention.
- Compounds B to F are compounds in which R 1 to R 13 in formula (4) in FIG. 2 are represented by groups or elements shown in the following table.
- FIG. 3 shows the results of alkaline phosphatase quantification 1.
- FIG. 4 shows the results of alkaline phosphatase staining 1.
- FIG. 5 shows the results of STAT3 activation case 1.
- FIG. 6 shows the expression level of the Oct_3Z4 gene.
- FIG. 7 shows the expression level of nanog gene.
- FIG. 8 shows the results of the average fluorescence intensity in the evaluation of the expression level 1 of the SSEA-1 antigen.
- FIG. 9 shows the structures of compounds ao of the present invention. Compounds a to o are compounds of formula (6) in FIG. ⁇ ⁇ ! ⁇ 9 is represented by the groups or elements shown in the table below.
- FIG. 10 shows the results of alkaline phosphatase assay 2 using the differentiation inhibitor of the present invention.
- FIG. 11 shows the results of the average fluorescence intensity in the evaluation of the expression level 2 of the SSEA-1 antigen.
- FIG. 12 shows the results of STAT3 activation case 2.
- FIG. 13 shows the result 1 of the ES cell subculture.
- FIG. 14 shows the result 2 of the ES cell subculture.
- FIG. 15 shows the effect of the differentiation inhibitor of the present invention on the maintenance of undifferentiated embryonic stem cells.
- FIG. 16 shows the effect of the differentiation inhibitor of the present invention on the maintenance of undifferentiated embryonic stem cells (stained diagram).
- FIG. 17 shows the structure of Compound II of the present invention. In the compound ⁇ , ⁇ to ⁇ 3 in the formula (10) in FIG. 17 are represented by groups or elements shown in the following table.
- FIG. 18 shows the structures of compounds 2 to 10 of the present invention.
- Compounds 2 to 10 are represented by the formula (9) in FIG. ⁇ 1 to!? 13 are represented by the groups or elements shown in the table below.
- FIG. 19 shows a staining diagram of alkaline phosphatase staining.
- a stem cell refers to another cell type that has a specialized function, that is, a cell that has finally differentiated or can be differentiated into another stem cell type that can be differentiated into a narrower range of cell types. .
- Totipotent stem cells are divided into any type of cell, including pluripotent cells and fully differentiated cells (ie, cells that can no longer differentiate into various cells). A cell that can be transformed.
- Pluripotent stem cells are cells that are not necessarily all types, but are capable of dividing into one of many different cell types.
- One example of a pluripotent cell is a hematopoietic stem cell, which can differentiate into various blood cell types such as lymphocytes and red blood cells.
- Embryonic stem cells are totipotent cells obtained from the morula or blastocyst stage of embryos, especially in the preimplantation stage, among stem cells, and are also called ES cells. Embryonic stem cells may also refer to pluripotent stem cells derived from primordial germ cells of an embryo or a fetus that have been determined to be sperm or ova. However, these cells are sometimes called embryonic germ (EG) cells and are sometimes distinguished from embryonic stem cells. As used herein, embryonic stem cells are of any animal species. Examples include embryonic stem cells such as primates, including humans, non-primate mammals, and birds.
- Totipotent refers to a state capable of differentiating into any cell type, including pluripotent cells and fully differentiated cells (ie, cells that can no longer differentiate into various cells).
- Pluripotency is a condition that does not necessarily come in all types, but can differentiate into one of many different cell types.
- Undifferentiated Undifferentiated is a condition in which a cell or any population of cells has the ability to differentiate into one or more more differentiated cells. It refers to a state of a cell or a cell population containing the cell.
- Feeder A feeder used for the purposes of describing the present invention refers to one on which totipotent stem cells are plated to provide an environment that assists in the growth of the plated totipotent stem cells.
- a feeder cell used for the purpose of describing the present invention refers to a non-totipotent stem cell on which totipotent stem cells are plated, and a non-totipotent stem cell is a plated totipotent stem cell.
- Provide an environment that helps the growth of Cell-derived components All components derived from cells, including components secreted from cells, contents, and cell membrane components.
- the present invention relates to a differentiation inhibitor capable of maintaining stem cells, preferably embryonic stem cells in an undifferentiated state, and to maintain proliferation, a culture method using the same, a culture solution using the same, and a culture prepared using the same.
- the differentiation inhibitor, the culture method, and the culture solution provided by the present invention can grow and maintain undifferentiated embryonic stem cells more easily and safely than ever before.
- the cell culture method containing the differentiation inhibitor of the present invention can also be used to screen for a specific differentiation-inducing factor and a useful combination of differentiation-inducing factors.
- the ability to grow undifferentiated embryonic stem cells using the differentiation inhibitor of the present invention and the culturing method can be used to identify embryonic stem cell lines having one or more genetic modifications having important therapeutic applications.
- any compounds can be used as long as they are chemically stable low molecular weight compounds and have an activity of maintaining stem cells in an undifferentiated state.
- the low molecular weight compound represented by (1) is mentioned.
- RR 2 ,, and R 4 may be the same or different and each represents an electron-withdrawing group, an electron-donating group, or a hydrogen atom.
- the electron donating group is a substituent capable of donating an electron to the benzene ring
- the electron withdrawing group is a substituent having a property of attracting ⁇ electrons on the benzene ring. It is also possible to define ⁇ 0 as an electron donating group and ⁇ > 0 as an electron withdrawing group using Hammett's substituent constant ⁇ (Basic Organic Reaction Theory, Shizunobu Hashimoto et al., Sankyo Publishing, 1997). .
- the ring represents a 5- to 8-membered ring containing at least one heteroatom in the ring.
- An alkylene group having 0 atoms represents a single bond.
- the pound that bonds to Ring A may be a group that forms a double bond.
- the alkylene group may have one or more electron-withdrawing groups, electron-donating groups or hydrogen atoms as substituents.
- G represents an electron withdrawing group, an electron donating group or an aromatic group which may have a hydrogen atom.
- the ring A may have one or more electron-withdrawing groups, Z or electron-donating groups as substituents other than the XG group.
- the ring A is a 5- or 6-membered ring containing at least one hetero atom in the ring selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom. It is also desirable that ring A is a 5- or 6-membered ring containing one nitrogen atom in the ring. In this case, the five-membered ring is desirably unsaturated, and the six-membered ring is desirably saturated.
- the alkylene group represented by X is an alkyl group, an acyl group, an alkoxy group, a nitro group, a hydroxycarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, a nitrile group and a halogen atom as a substituent. It is preferable that the compound has at least one selected group and Z or atom.
- examples of the general formula (1) include a tetrahydroisoquinoline derivative represented by the formula (2) and an indole derivative represented by the general formula (3).
- RR 2 , R 3 , R 4 , X and G are as defined above.
- R 5 , R 6 , R 7 , R 8 , and R 9 may be the same or different, and represent an electron-withdrawing group, an electron-donating group, or a hydrogen atom.
- R 1 R 2 , R 3 , RX and G are as defined above.
- R 5 and R 6 may be the same or different and each represents an electron-withdrawing group, an electron-donating group, or a hydrogen atom.
- tetrahydroisoquinoline derivative represented by the general formula (2) examples include: Examples include compounds and salts having a structure represented by the formula (4) or the formula (5).
- ⁇ 1 to ⁇ 3 may be the same or different and each represents an electron withdrawing group, an electron donating group or a hydrogen atom.
- alkyl group, Ashiru group, an alkoxy group, a nitro group, hydroxycarboxylic Poni group, nitrile group, an alkoxycarbonyl group, Aminoka Ruponiru group, a halogen atom ⁇ Pi group or nuclear S selected from the group consisting of hydrogen atom can give.
- R 8 , R 9 and R 10 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group.
- R 6 and R 7 are lower alkyl groups which may be the same or different,
- R 11 is a hydrogen atom, a halogen atom, a nitro group or a lower alkoxy group, and
- R 12 is a hydrogen atom An atom, a lower alkyl group, a lower acyl group, or a lower alkoxy group, wherein R 13 is a hydroxycarbonyl group, a nitrile group, an aminocarbonyl group, or a lower alkoxycarbonyl group;
- Examples of the lower alkyl group represented by R include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentinole, isopenpentole, neopentinole, 1-methylpropyl, Examples include n-hexyl, isohexyl, 1,1-dimethinolebutynole, 2,2-dimethylbutyl, 3,3-dimethylinobutynole, 3,3-dimethylinopropyl, and 2-ethylbutyl. Preferably, it is methyl.
- Examples of the lower alkoxy group represented by R include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentoxy, hexyloxy, heptoxy and octyloxy. . Preferred is methoxy.
- halogen atom represented by R examples include fluorine, chlorine, bromine, and iodine, and are preferably chlorine or bromine.
- Examples of the lower acetyl group represented by R include formyl, acetyl, propionyl, butyryl and the like, with acetyl being preferred.
- the lower alkyl group which may form a cyclic structure represented by R is cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl, cyclooctyl, etc., preferably cyclopentyl, cyclohexyl , Is the mouth of the mouth.
- the lower alkoxycarbonyl represented by R includes methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and the like, and is preferably methoxycanoleponyl or ethoxycarbonyl.
- Examples of the aminocarbonyl represented by R include, for example, -C0NR 2 (R represents a hydrogen atom which may be the same or different, a lower alkyl group exemplified above, or a phenyl group which may have a substituent. ) And the like.
- Examples of the secondary aminocarbonyl group represented by R include —C0 HR (representing a lower alkyl group and a phenyl group which may have a substituent) as exemplified above.
- Examples of the tertiary aminocarbonyl group include, for example, -C0NR 2 (R represents a lower alkyl group which may be the same or different, and a fuynyl group which may have a substituent) Is mentioned.
- Examples of the aminoalkyl group represented by R include, for example, one (CH 2 ) n -NR 2 (n represents 1 to 8, but preferably 1. Further, R is a hydrogen atom which may be the same or different, Lower alkyl group, lower alkyl group that may form a cyclic structure (cyclic structure may contain 1 to 3 heteroatoms such as nitrogen and oxygen), substituent that may have a substituent Represents a phenyl group).
- the double-sided broken line in the formula (4) represents a single bond or a double bond.
- geometric isomers exist in the wavy portion (two places).
- the configuration of these geometric isomers is not particularly limited, and may be each independently E-form or Z-form.
- the compound of the present invention is a compound of the geometrical isomer in a pure form based on these geometric isomers. It can be any mixture.
- R 8 and R 9 are hydrogen atoms
- R 1 Q is a hydrogen atom or a lower alkyl group
- R 5 is a hydrogen atom, a lower acyl group, or a lower alkyl group
- 6 and R 7 is a lower alkyl group which may be the same or different
- R 1 1 is a hydrogen atom, a halogen atom, a nitro group, a lower alkoxy shea group or a lower alkoxycarbonyl group
- R 1 2 is a hydrogen atom, a lower alkyl group, a lower acyl group, or a lower alkoxy group.
- R 1 3 is ⁇ amino carbonyl group, the compound represented by the general formula (7) below .
- examples of the more specific compound included in the general formula (4), which is a tetrahydroisone quinoline derivative are as follows.
- ⁇ 1 to!? 4 and R 6 to R 12 include the same or different electron-withdrawing groups, or groups or atoms selected from electron-donating groups or hydrogen atoms.
- R 6 to R 12 include the same or different electron-withdrawing groups, or groups or atoms selected from electron-donating groups or hydrogen atoms.
- R 1 to R 4 and R 6 to Ri 2 are the same or different and are an alkyl group, an alkenyl group, an alkyl group, a phenyl group, a naphthyl group, a furyl group, a chenyl group, an alkoxy group, an alkylamino group, an alkylcarbonyl Group, benzoyl group, naphthoyl group, furoyl group, tenyl group, dialkylcarbamoyl group, acetyl group, butanol group, methoxycarbonyl group, cycloalkyl group, benzyloxy group, adamantyloxy group, nitro group A group selected from the group, or a halogen atom or a hydrogen atom Is mentioned.
- R 6 ⁇ R 1 2 alkyl group, Asechiru group, an alkoxycarbonyl group, a nitro group, it Motoma other selected from the group consisting of a halogen atom or a hydrogen atom is the atomic desirable .
- Examples of the compound included in the general formula (5) include the following.
- a pharmaceutically acceptable salt is desirable.
- hydrochloride, sulfate, phosphate, hydrobromide, acetate, maleate, fumarate, succinate, methanesulfonate, p-toluenesulfonate, citrate, tartaric acid A salt or the like may be formed.
- ester compounds of the compounds represented by the general formulas (4) and (5) are also included in the scope of the present invention, and include, for example, carboxylic acid esters, sulfonic acid esters, and inorganic acid esters.
- Examples of the indole derivative represented by the general formula (3) include a compound represented by the following formula (6).
- ? 1 to! ⁇ 9 represent the same or different electron withdrawing groups, electron donating groups or hydrogen atoms.
- preferably! ? 1 to!? 9 represent a group or atom selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyl group, a nitro group, an acetyloxy group, an aminoalkyl group, an acetyloxyalkyl group, an aminobutyl group and a hydrogen atom.
- R and R 2 are hydrogen atoms
- R 3 is an acetooxy group or a hydroxyl group
- R 4 is a hydrogen atom, a dialkylaminoalkyl group, a cyclic alkylaminoalkyl group, or a hydroxyalkylaminoalkyl.
- R 5 is a lower alkyl group or an arylaminobutyl group
- R 6 is a dinitro group
- R 7 to R 9 may be the same or different. Desirably, it is an alkyl group, a lower alkoxy group, or a hydrogen atom.
- Examples of the compound included in the general formula (6) include the following. 2-Methyl-3- 2-nitro-1-phenyl-1H-indole-6-ol
- the compound of the present invention can be produced by the methods described below, methods analogous thereto, or known methods.
- the method for producing the compound represented by the formula (9) is shown below.
- thioether derivative (I) and the phenylazoacetamide derivative (II) are converted to a suitable solvent that does not adversely affect the reaction (for example, amides such as dimethylformamide and dimethylacetamide, ethers such as tetrahydrofuran, , Toluene and other aromatic hydrocarbons) and refluxing until the raw materials are exhausted.
- a suitable solvent for example, amides such as dimethylformamide and dimethylacetamide, ethers such as tetrahydrofuran, , Toluene and other aromatic hydrocarbons
- the derivative (I) can be prepared by a known method (for example, described in Khim. Geterotsikl. Soedin., No. 7, ⁇ 995 (1990)), or It can be purchased from commercial products. Specifically, it is as shown in Table 1 below. table 1
- the fenylazoacetoamide derivative (II) can be obtained by a known method (Materialy Ural 'sk. Soveshch. Po Spektroskopii, 4th, Sverdlovsk 1963, p205 (1965), Bulletin detreu Polonaise des Sciences, Serie des Sciences Chimiques, 14). (1), p29 (1966), Am. Chem. Soc., Div. Org. Coatings, Plastics Chem. Preprints, 23 (2), p486 (1963), Zhurnal Obshchei Khimii, 35 (3), p559 (1965) , Zhurnal Obshchei Khimii, 32, p526 (1962)).
- the compound represented by the formula (9) can also be synthesized by the following scheme.
- the compound (IV) obtained by reacting a benzylcarbinol derivative with a 2-cyanoacetamide derivative in the presence of sulfuric acid is combined with a diazonium salt (V) in an aqueous alcohol solution that does not adversely affect the reaction. It is obtained by reacting in the presence.
- a diazonium salt (V) in an aqueous alcohol solution that does not adversely affect the reaction. It is obtained by reacting in the presence.
- Various derivatives of the benzylcarbinol derivative can be purchased from commercial products, and can be obtained by a known method (for example, J. Gen. Chem. USSR, No. 6, pl263 (1936).
- the salt can be derived from a commercially available aminobenzene derivative by an aqueous solution of hydrochloric acid or sodium nitrite by a known method.
- R 5 is a methyl group in the compound represented by the formula (9) is described below.
- a suitable solvent that does not adversely affect the reaction for example, nitriles of acetonitrile, ethers such as tetrahydrofuran, aromatic hydrocarbons such as benzene and toluene
- sodium carbonate to dissolve and dissolve methyl iodide in a suitable solvent that does not adversely affect the reaction
- a suitable solvent that does not adversely affect the reaction for example, amides such as dimethylformamide and dimethylacetamide, and ethers such as tetrahydrofuran.
- Benzene, toluene and other aromatic hydrocarbons can be produced by slowly dropping and refluxing.
- R 5 is an acetyl group in the compound represented by the formula (9)
- the compound represented by the formula (9) is dissolved in an appropriate solvent that does not adversely affect the reaction (for example, amides such as dimethylformamide and dimethylacetamide), and thionyl chloride is appropriately dissolved without affecting the reaction. It can be produced by adding a solution dissolved in a suitable solvent (for example, amides such as dimethylformamide and dimethylacetamide) dropwise in an ice bath. '
- the compound can be produced by adding a hydroxylation sphere and a compound represented by the formula (9) to ethanol and refluxing the mixture.
- the compound represented by the formula (12), the corresponding primary or secondary amine, HOBt (Advanced ChemTech, USA) and triethylamine are converted into a suitable solvent (for example, dimethylformamide, dimethylacetate) which does not adversely affect the reaction.
- a suitable solvent for example, dimethylformamide, dimethylacetate
- Dissolve in amides such as amides and add HBTU (Advanced ChemTech, USA) to a suitable solvent that does not adversely affect the reaction for example, amides such as dimethylformamide and dimethylacetamide, and halogens such as dichloromethane) (E.g., a system solvent). It can be produced by stirring at room temperature.
- the compound represented by the general formula (4) exists in a solvent capable of dissolving in an appropriate solvent, as it is, or in a reduced form represented by the following formula (15), or as a mixture thereof. You can.
- the compound of the present invention or a salt thereof obtained by force can be isolated and purified by ordinary separation means such as, for example, recrystallization, distillation, and mouth chromatography.
- ordinary separation means such as, for example, recrystallization, distillation, and mouth chromatography.
- the compound of the present invention when obtained in a free form, it can be converted to a salt by a known method or a method analogous thereto.
- salt when obtained with salt, It can be converted into a free form or another salt by a known method or a method analogous thereto.
- the compound or its salt may have an asymmetric carbon in some cases, but when it is obtained as an optically active mixture (racemate), it can be separated into its optical activities by ordinary optical resolution means.
- the concentration of the differentiation inhibitor of the present invention in the range of 0.1 ng / m1 to 1 mg Zm1, preferably 10 ng Zm1 to 100 ⁇ g / m1, and more preferably More preferably, it is used in the range of 100 ng / m 1 to 10 ⁇ g / m 1.
- the differentiation inhibitor of the present invention contains a low-molecular compound that maintains undifferentiation of embryonic stem cells without activating STAT3 (signal transducer and activator of transcription 3), particularly a tetrahydroisoquinoline derivative.
- Embryonic stem cells of a specific mouse strain remain undifferentiated by LIF regardless of the presence or absence of feeder cells consisting of fibroblasts derived from mouse embryos. LIF is known to transmit downstream signals through activation of STAT3 (Matsuda et al., EMB0 Journal, 18, 15, P 4261, 1999).
- the differentiation inhibitor of the present invention includes low molecular weight compounds that maintain undifferentiated embryonic stem cells without activating STAT3. In other words, it includes low molecular weight compounds having an activity to maintain undifferentiated embryonic stem cells by an action different from that of LIF.
- the Nanog gene was identified as one of the molecules that regulates undifferentiation of embryonic stem cells without LIF and STAT3 (Mitsui et al., Cell, 113, p631, 2003, Chambers et al., Cell, 113, p643, 2003).
- the presence of the N anog gene has been confirmed in mice and humans.If expression is suppressed by gene disruption, the totipotency of embryonic stem cells is lost, and conversely, the expression of the N anog gene is increased by overexpressing the N anog gene
- a substance capable of increasing the expression level of the Nanog gene for example, a low-molecular compound, can be used for maintaining the undifferentiated state of embryonic stem cells, that is, for culturing totipotent embryonic stem cells.
- the Nanog gene since the strong expression of the Nanog gene does not activate STAT3, the Nanog gene maintains undifferentiated embryonic stem cells independently of LIF and STAT3. That is, it is suggested that a substance capable of increasing the expression level of the Nanog gene, for example, a low-molecular compound, can be used for culturing even rat embryonic stem cells in which the effect of maintaining undifferentiation by LIF has not been observed. Is done.
- the differentiation inhibitor of the present invention includes a low-molecular compound that increases the expression level of the Nanog gene. That is, the differentiation inhibitor of the present invention includes a low-molecular compound that exerts the ability to maintain undifferentiation of embryonic stem cells through an increase in the expression level of the Nanog gene.
- the differentiation inhibitor of the present invention includes a low molecular compound having an activity of maintaining an undifferentiated state of a cell without using STAT3.
- the differentiation inhibitor of the present invention can be used by being added to any mammalian cell culture basal medium which is a basal medium for animal cell culture.
- animal cell basic medium include, but are not limited to, Dalbecco's modified single medium: DMEM, knockout DMEM, Glasgow MEM: GMEM, RPMI1640, IMDM (all manufactured by Invitrogenlnvitrogen, USA) Not done.
- the cell culture medium is Dulbecco's modified Eagle's medium (DMEM).
- DMEM Dulbecco's modified Eagle's medium
- these basal media can be used by adding proteins related to cell growth and differentiation control, such as serum or serum substitutes, various growth factors, and cytokines. Further, any compound may be added.
- the serum can be any serum that provides nutrients that are effective in maintaining the growth and viability of embryonic stem cells if they are stem cells, or serum-based solutions.
- examples of such sera include fetal calf serum (FCS), bovine serum (CS), and horse serum (HS).
- Serum substitutes are well known to those skilled in the art, such as protein, Amino acids, lipids, vitamins and the like can be used alone or in combination. Proteins include insulin, transferrin, albumin, peptone, FGF (Fibroblast Growth Factor), EGF (Epitherial Growth Factor), etc.
- the serum is fetal calf serum.
- the fetal calf serum is provided at a concentration between about 25% and about 1%.
- the concentration of fetal calf serum in the cell culture medium is 15%.
- the serum replacement is Knockup Serum Replacement: KSR (Invitrogen, USA).
- Cell growth factors that can be added include hepatocyte growth factor (HGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), nerve growth factor (NGF ), Platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor (TGF), bone morphogenetic factor (BMP), stem cell factor (SCF), Wnt, etc. Not limited.
- HGF hepatocyte growth factor
- EGF epidermal growth factor
- FGF fibroblast growth factor
- IGF insulin-like growth factor
- NGF nerve growth factor
- PDGF Platelet-derived growth factor
- VEGF vascular endothelial growth factor
- TGF transforming growth factor
- BMP bone morphogenetic factor
- SCF stem cell factor
- Wnt Wnt, etc.
- cytokines include, but are not limited to, interleukin (IL) and granulocyte-macrophage colony-stimulating factor
- the compound to be added is not particularly limited, but may be an agonist or an antagonist to an arbitrary protein, or may be an arbitrary phosphorylation inhibitor.
- PD 98059 from Cell Signaling Technology
- 6-bromoindirubin-3 oxime is provided.
- the cell culture medium also contains antioxidants (reducing agents) (eg,] 3-mercaptoethanol).
- antioxidants reducing agents
- 3-mercaptoethanol has a concentration of about 0. ImM.
- Other antioxidants such as monothioglycerol or dithiothreitol (DTT), alone or in combination, can be used for similar effects.
- Still other equivalent materials are well known to those skilled in the art of cell culture.
- the active ingredient thereof can be used together with an arbitrary culture medium or fixed to the culture medium.
- a porous material can be used as a culture substrate.
- the porous body refers to a substrate having a large number of fine pores, and its material, thickness, shape, dimensions, and the like are not particularly limited.
- the material of the porous body may be an organic material, an inorganic material, or a composite material composed of an organic material and an inorganic material.
- the shape of the porous body may be any of a flat plate, a sphere, a rod, a fiber, and a hollow.
- a film, a sheet, a membrane, a plate, a nonwoven fabric, a filter paper, a sponge, a woven fabric, a knit, a lump, Yarns, hollow yarns, particles and the like In culturing cells, nonwoven fabrics are more preferable in view of the fact that the size of the pores supporting the cells can be easily controlled so that the cells can be cultured three-dimensionally, and the ease and cost of preparing a base material.
- the average pore size is preferably not less than 0.1 lm and not more than ⁇ . , 1 m or more and 50 / m or less are more preferable.
- the fiber diameter is not particularly limited, but is preferably 0.03 denier or less.
- the above porous body may be subjected to a surface coating treatment with a polymer compound in order to improve cell adhesion, differentiation maintenance function, and proliferation ability.
- a macromolecular substance is a monomer in which one or more types of repeating structural units are connected in one, two, or three dimensions. Refers to a substance having a molecular weight of several hundred or more.
- Polymer substances can be broadly classified into three groups: natural polymer substances, semi-synthetic polymer substances, and synthetic polymer substances, and any of the polymer substances can be used in the present invention.
- natural polymer substances include sugars and gelatins such as myriki (mica), asbestos (asbestos), dara fight (graphite), diamond, starch, cellulose, alginic acid, etc., fibronectin, and fibrinogen. , Laminin, collagen, etc.
- Semi-synthetic polymer substances include glass, cellulose nitrate, cellulose acetate, rubber hydrochloride, carboxymethyl cellulose, etc.
- Synthetic polymer substances examples include polyphosphonitrile chloride, polyethylene, polychlorinated vinyl, polyamide, polyethylene terephthalate, polysulfone, polyacrylonitrile, polyvinyl alcohol, polymethyl methacrylate, polyhydroxyethyl methacrylate, and polydimethyl amide.
- the culture substrate is gelatin. In another embodiment, it is a matrix (BD Biosciencs ⁇ ).
- a method and apparatus for separating and culturing stem cells or embryonic stem cells from a population of a plurality of different cells by using a culture substrate on which the differentiation inhibitor of the present invention is fixed as a cell capturing material can be provided. That is, a cell-containing solution containing stem cells or embryonic stem cells and cells to be removed is introduced into a container filled with a cell-capturing material comprising a culture substrate such as a porous body in which the differentiation inhibitor of the present invention is fixed. A stem cell or embryonic stem cell is captured by a cell capturing material, and a cell to be removed is derived from the outside of the container and then cultured together with the container.
- the container can be used for cell culture.
- the cells to be removed refer to all cells other than stem cells or embryonic stem cells. Also, cells that have differentiated from stem cells or embryonic stem cells and have lost pluripotency are included in this.
- the cell-containing liquid to be introduced into the cell trapping material may be any cell liquid containing stem cells or embryonic stem cells. For example, blood, bone marrow, fragment tissue fluid, or culture of stem cells or embryonic stem cells Liquid and the like.
- the present invention relates to a method for growing embryonic stem cells as well as stem cells.
- a stem cell grown using the differentiation inhibitor of the present invention can also provide a culture of embryonic stem cells.
- the cells cultured using the differentiation inhibitor of the present invention include all stem cells and embryonic stem cells that can be obtained using known methods and materials.
- the stem cells include stem cells that can be obtained by the following known methods. Bone marrow cells ("Bone marrow transplantation guide” by HJ Dieg, HG Talingemann, GL Phillips / Shinpei Kasakura), bone marrow stem cells (Osawa et al., Science, 273, p242-245, 1996, Goodell et al., JE Med.
- embryonic stem cells to be cultured can be obtained using the following known methods and materials.
- Mouse embryonic stem cells Evans et al., Nature, 292, pl54, 1981.
- Pesticide ES cells Schellander et al., Theriogenology, 31, pl5-17, 1989, swine ES cells: Strojek et al., Theriogenology, 33: p901, 1990, sheep ES cells: Handyside, Roux, s Arch. Dev. Biol., 196: pl85, 1987, Hamster ES cells: Doetschman Biol., 127, p224, 1988, Monkey ES cells: Thomson et al., Proc. Natl. Acad. Sci.
- Powered cynomolgus ES cells Suemori et al., Dev. Dyn. 222, P273, 2001
- human ES cells Thomson et al., Science, 282, pll45, 1998, Reubinoff et al., NatureBiotech, 18, p399, 2000
- human EG cells Gearhart et al., Proc. Natl. Acad. Sci. USA, 95, pl3726, 1998.
- Mouse embryonic stem cells (129SV and C57 / BL6) can be purchased from Dainippon Pharmaceutical.
- the differentiation inhibitor provided by the present invention can be used for all stem cells and embryonic stem cells, but is preferably used for mammalian stem cells and embryonic stem cells, and is preferably used for primate stem cells and embryonic stem cells. Is preferred.
- cells and embryonic stem cells can be cultured in an undifferentiated state using the differentiation inhibitor of the present invention.
- the degree of undifferentiation of stem cells, preferably embryonic stem cells, cultured using the differentiation inhibitory lj of the present invention can be confirmed by measuring the activity of alkaline phosphatase (ALP) present on the cell membrane of the stem cells.
- ALP activity is known to be maintained in undifferentiated embryonic stem cells and decreased upon differentiation (Williams et al., Nature, 336, p684, 1988; Thomson et al., Science, 282, pll45, 1998) .). Examples of such methods include staining using an insoluble substrate, and spectrophotometric measurement using a water-soluble substrate to detect the activity of ALPHA phosphatase (ALP).
- ALP activity can be quantified by spectrophotometry.
- pNPP paranitrophenyl phosphate
- ALP present on the cell membrane hydrolyzes pNPP to produce paranitrophenol.
- the alkaline phosphatase activity can be quantified.
- the ALP activity of embryonic stem cells cultured with the addition of the differentiation inhibitor of the present invention was significantly higher than that of control embryonic stem cells cultured in a medium containing no differentiation inhibitor. Shows that it has high ALP activity. That is, it is confirmed that the differentiation inhibitor of the present invention can proliferate while maintaining the undifferentiated state of embryonic stem cells. Recognized.
- ALP activity can be detected by ALP staining.
- To the cells on the culture dish add a reaction solution containing phosphate and diazoum salts as substrates. Phosphoric acid ester salts are hydrolyzed by allelic phosphatase present in the form of cell membrane, followed by coupling reaction with diazonium salts to form azo dyes, which precipitate in the ALP active site.
- the ALP activity of the cells can be quantified, that is, the undifferentiated degree of the cells can be quantified.
- ALP staining of embryonic stem cells cultured with the differentiation inhibitor of the present invention by the method described in Example 1 (6) showed that ALP activity was significantly higher than that of control cells without the differentiation inhibitor. That is, it is confirmed that the differentiation inhibitor of the present invention can proliferate while maintaining the undifferentiated state of embryonic stem cells.
- the degree of undifferentiation of embryonic stem cells can be confirmed by measuring the expression level of Oct-3 / 4 gene.
- the Oct-3 / 4 gene is a transcription factor belonging to the P0U family and is specifically expressed in undifferentiated states in embryonic stem cells and embryonic cancer cells (EC cells) (Okamoto et al., Cell, 60, p461, 1990). In embryonic development, it is expressed only in the undifferentiated cell lineage (Scholer, Trends Genet, 7, p323, 1991). Furthermore, homozygous mice of the Oct-3 / 4 gene disrupted mouse stop development at the blastocyst stage.
- a real-time PCR method has a wide dynamic range, and enables simple and reliable quantitative measurement.
- Taq Man probe using ABIPRISM7700TM (Applied Biosystems) for real-time PCR technology And the method using LightCyclerTM (Roche Diagnostics).
- changes in the amount of DNA synthesized in each cycle can be detected in real time under a rapid reaction cycle in which the temperature cycle of PCR is completed in tens of minutes.
- Four types of DNA detection methods for real-time PCR use DNA binding dyes (interactors), hybridization probes (kissing probes), TaqMan probes, and Sunrise Uniprimers (molecular beacons). There is a method.
- the expression level of the Oct-3 / 4 gene can be analyzed using a DNA binding dye, for example, SYBR Greenl.
- SYBR Greenl is a dye that binds specifically to the duplex of DNA, and the intrinsic fluorescence intensity is enhanced by binding to the duplex. By adding SYBR Greenl during the PCR reaction and measuring the fluorescence intensity at the end of each cycle of the extension reaction, an increase in the PCR product can be detected.
- primers are designed based on the sequence of the Oct-3 / 4 gene using commercial gene analysis software, etc., as in normal PCR. Since SYBR Greenl also detects non-specific products, optimal primer settings are required.
- the goal of quantitative PCR is to determine the amount of DNA of interest per sample. For this, it is necessary to evaluate the amount of sample initially added to the reaction system.
- another DNA that serves as an internal standard that reflects the sample volume can be measured separately from the target DNA, and the sample volume initially added to the reaction system can be corrected.
- the internal standard used for the purpose of correcting the sample amount may be a housekeeping gene which is generally considered to have no difference in expression level between tissues.
- genes such as glyceraldehyde aldehyde phosphate dehydrogenase (GAPDH), a major glycolytic enzyme, actin or actin, a component of the cytoskeleton, and S26, a liposome constituent protein.
- GPDH glyceraldehyde aldehyde phosphate dehydrogenase
- actin or actin a major glycolytic enzyme
- S26 a liposome constituent protein
- the expression level of the Oct-3 / 4 gene can be determined for cells exposed to the differentiation inhibitor of the present invention. Not exposed to the differentiation inhibitor, that is, significantly different from the Oct-3 / 4 gene expression level in control cells induced to differentiate from embryonic stem cells A compound having an activity capable of maintaining the expression level of the Oct-3 / 4 gene is considered to be a differentiation inhibitor that maintains undifferentiation of embryonic stem cells.
- SSEA Stage Specific Embryonic Antigen
- a surface antigen such as SSEA-1
- a specific antibody that recognizes the antigen
- a second antibody second antibody conjugated to a reporter such as a fluorescent label.
- Incubation with allows labeling.
- cells expressing the target antigen become fluorescent.
- the labeled cells can then be counted and sorted using standard methods, for example using a flow cytometer. The numbers of labeled and unlabeled cells can then be compared to determine the effect of the culture medium of interest.
- the cells after exposure to an unlabeled cell surface marker antibody, the cells, in an ELISA (enzyme-linked immunosorbent assay) format, are specific for an anti-cell surface antigen antibody (eg, an anti-SSEA-1 antibody).
- an anti-cell surface antigen antibody eg, an anti-SSEA-1 antibody
- a second antibody can be exposed from which the number of cells expressing the desired surface antigen can be quantified colorimetrically or by measuring fluorescence. Still other methods for quantifying cells expressing surface antigens are well known to those skilled in cell culture.
- the improved differentiation inhibitor, culture method and culture solution for the growth of stem cells or embryonic stem cells provided by the present invention can be applied to all techniques in which stem cells or embryonic stem cells are useful. It is expected that.
- the cells produced using the differentiation inhibitor of the present invention, the culture method and the culture solution can be differentiated, used for cell transplantation, or used for constructing an artificial tissue in combination with the use of an artificial support tissue. It can be transplanted to or used as an artificial organ.
- the use of stem cells for cell transplantation therapy and tissue engineering can solve the problems of conventional transplantation therapy, including autologous transplantation, such as tissue deficiency after transplantation of a donor and insufficient donor.
- the cultured cells or tissues may be returned to the same person as the collected person or transplanted to another person for treatment.
- the cells and the like of the present invention can be used for any of them.
- the differentiation inhibitor of the present invention a culture method using the same, a culture of unmodified and modified stem cells, preferably embryonic stem cells, obtained by a culture solution containing the same, is a stem cell, preferably an embryonic stem cell.
- a putative stem cell or embryonic stem cell differentiation inducer can be added to a cell culture grown using the methods described above.
- Substances capable of inducing differentiation into three germ layer lineages as compared to control cell cultures deficient in putative stem cell or embryonic stem cell differentiation-inducing substances are identified as embryonic stem cell differentiation-inducing factors.
- the differentiation inhibitor Z or compound or a salt thereof according to the present invention has excellent stem cell undifferentiated maintenance and proliferation ability, and is therefore used as a therapeutic agent for tissues or organs damaged by disease or trauma.
- Target diseases include, for example, burns, intractable skin ulcers, pimples, hypertrophic scars, nevus, and tattoos in the skin-related field, fractures and osteoporosis in the bone field, and osteoporosis in the cartilage field.
- Parkinson's disease Huntington's disease
- Alzheimer's disease trauma to the limb due to trauma, head and neck surgery, damage associated with thoracic surgery, and facial nerve Paralysis, diaphragmatic nerve injury, pelvic nerve injury, etc., periodontal disease in teeth, alveolar bone damage due to alveolar pyorrhea, odontosis, male pattern baldness in hair, congenital abnormalities in cornea, endothelial cell compensation Insufficiency, cloudiness due to corneal infection, corneal degeneration, corneal malformation, etc.Vascular-related hypertension, chronic arterial occlusion, ischemic heart disease, etc.
- Examples include, but are not limited to, diabetes in the gut and hepatitis, cirrhosis, and liver failure in the liver.
- the differentiation inhibitor and Z or the compound of the present invention prevent and prevent the above diseases.
- Oral or parenteral administration is possible as a therapeutic agent.Does it mix with a pharmaceutically acceptable carrier and is usually administered orally as a solid preparation such as tablets, capsules, granules, and powders? Injection, suppository, intravenous, subcutaneous, intramuscular etc. Is administered parenterally as a sublingual tablet or the like. It may also be administered sublingually, subcutaneously or intramuscularly as a sustained release formulation such as sublingual tablets and microcapsules.
- the daily dose varies depending on the severity of the symptoms; age, sex, weight, and sensitivity difference of the subject; timing of administration, interval, properties of pharmaceutical preparations, preparation, type; type of active ingredient, and is particularly limited.
- the dosage for use in the livestock or fisheries field is the same as described above, but about 0.01 to 30 mg, preferably about 0.1 to 10 mg per kg body weight of the organism to be administered, usually 1 to 3 times a day. It is divided and administered.
- the content of the compound of the present invention in the pharmaceutical composition is about 0.01 to 100% by weight of the whole composition.
- various organic or inorganic carrier substances commonly used as pharmaceutical materials are used, and excipients, lubricants, binders, disintegrants in solid preparations; solvents in liquid preparations, Formulated as solubilizers, suspending agents, isotonic agents, buffers, soothing agents, etc.
- pharmaceutical additives such as preservatives, antioxidants, coloring agents and sweeteners can be used.
- Preferable examples of the above-mentioned excipients include lactose, sucrose, D-mannitol, starch, microcrystalline cellulose, light caffeic anhydride and the like.
- Preferable examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- Preferable examples of the binder include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, and polypyrrolidone.
- Preferable examples of the above disintegrant include starch, carboxymethyl cellulose, carboxymethylcellulose canolesum, cross force / remelose sodium, carboxymethyl starch sodium and the like.
- Preferred examples of the above-mentioned solvent include water for injection, alcohol, propylene glycol, macrogol, sesame oil, and corn oil.
- Preferred examples of the solubilizer include: Examples include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
- the suspending agent include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate;
- surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate
- hydrophilic polymers such as polyvinylinolea / recol, polyvinylinolepyrrolidone, sodium / reoxymethylcellulose sodium, methylcellulose, hydroxymethinolecellulose, hydroxyshethylcellulose, and hydroxypropylcellulose.
- Preferable examples of the tonicity agent include sodium chloride, glycerin, D-mannitol and the like.
- Preferable examples of the buffer include, for example, buffers such as phosphate, acetate, carbonate, and citrate.
- Preferred examples of the soothing agent include benzyl alcohol and the like.
- Suitable examples of the above preservatives include, for example, paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- Preferable examples of the antioxidant include sulfite, ascorbic acid and the like.
- a suspension agent, a solubilizing agent, a stabilizing agent, a tonicity agent, a preservative, and the like are added to the differentiation inhibitor and / or the compound of the present invention, and a vein, subcutaneous, or intramuscular injection is prepared by a known method. can do. At that time, if necessary, it can be lyophilized by a known method.
- the compound of the present invention is administered, for example, to humans, the compound itself is mixed with an appropriate pharmacologically acceptable carrier, excipient, or diluent, and is orally or parenterally administered as a pharmaceutical composition. Can be safely administered.
- Examples of the pharmaceutical composition include oral preparations (eg, powders, granules, capsules, tablets), parenteral preparations (eg, injections, 10 drops, external preparations (eg, nasal preparations, transdermal preparations, etc.) ), Suppositories (eg, rectal suppositories, vaginal suppositories, etc.)].
- oral preparations eg, powders, granules, capsules, tablets
- parenteral preparations eg, injections, 10 drops, external preparations (eg, nasal preparations, transdermal preparations, etc.)
- Suppositories eg, rectal suppositories, vaginal suppositories, etc.
- the differentiation inhibitor and / or the compound of the present invention may be a dispersant (eg, Tween 80 (manufactured by Atlas Powder Co., USA), HCO 60 (manufactured by Nikko Chemicals) Polyethylene Lendacol, carboxymethylcellulose, sodium alginate, etc.), Aqueous injections with preservatives (eg, methylparaben, propylparaben, benzyl alcohol, etc.), tonicity agents (eg, sodium chloride, mannitol, sorbitol, dextrose, etc.), or olive oil, sesame oil, cottonseed oil, corn oil, etc.
- a dispersant eg, Tween 80 (manufactured by Atlas Powder Co., USA), HCO 60 (manufactured by Nikko Chemicals) Polyethylene Lendacol, carboxymethylcellulose, sodium alginate, etc.
- preservatives eg, methylparaben, propylparaben, benz
- Inhibitor Z or compound can be added to excipients (eg, lactose, sucrose, starch) Disintegrant (eg, starch, calcium carbonate, etc.), binder (eg, starch, gum arabic, carboxymethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose, etc.) or lubricant (eg, talc , Magnesium stearate, polyethylene dalicol 600, etc.) and compression molding, and then, if necessary, coating by a method known per se for taste masking, enteric or sustained purposes.
- excipients eg, lactose, sucrose, starch
- Disintegrant eg, starch, calcium carbonate, etc.
- binder eg, starch, gum arabic, carboxymethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose, etc.
- lubricant eg, talc , Magnesium stearate, polyethylene d
- the coating agent examples include hydroxypropyl methylcellulose, ethinoresenorelose, hydroxymethinolese / rerose, hydroxypropinoresenorelose, polyoxyethylene glycolone, and the like. Tween 80, Punoleronic F 6 8.
- eudragit manufactured by Rohm, Germany, methacrylic acid / acrylic acid copolymer
- dyes eg, Bengala , Titanium dioxide, etc.
- an intermediate phase may be provided between the enteric phase and the drug-containing phase by a method known per se for the purpose of separating both phases.
- the dehydration inhibitor and Z or the compound of the present invention can be made into a solid, semi-solid or liquid external administration preparation.
- the compound of the present invention can be used as it is or as an excipient (eg, glycol, mannitol, starch, microcrystalline cellulose, etc.), a thickener (eg, natural gums, cellulose derivatives, acrylic acid polymer) Etc.) and mixed to form a powdery composition.
- the liquid form should be an oily or aqueous suspension almost as in the case of injections.
- an aqueous or oily gel or ointment is preferred.
- pH regulators eg, carbonate, phosphoric acid, citric acid, hydrochloric acid, sodium hydroxide, etc.
- preservatives eg, esters of paraoxybenzoate, chlorobutanol, benzalkonium chloride, etc.
- oily base used in the above composition examples include glycerides of higher fatty acids (eg, cocoa butter, witepsol (manufactured by Dynamite Nobel, Germany), etc.), and intermediate fatty acids [eg, migliols (manufactured by Dynamite Nobel Or vegetable oil (eg, sesame oil, soybean oil, cottonseed oil, etc.).
- aqueous base examples include polyethylene glycols and propylene glycol
- examples of the aqueous gel base include natural gums, cellulose derivatives, vinyl polymers, and acrylic acid polymers.
- the prodrugs of the compounds (9) and (10) refer to compounds which are converted into compounds (9) and (10) having a stem cell proliferating action in vivo by a metabolic reaction with an enzyme, gastric acid or the like.
- prodrugs of compounds (9) and (10) when compounds (9) and (10) have an amino group, compounds in which the amino group is acylated, alkylated or phosphorylated (E.g., when the amino group of compound (9) or (10) is dicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl) ) Methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation, bivaloyloxymethylation, tert-butylated compound, etc.); and when compounds (9) and (10) have carboxyl, Are esterified or amidated (e.g., compounds (9) and (1 0) is carb
- the prodrugs of Compounds (9) and (10) can be prepared under physiological conditions as described in Hirokawa Shoten, 1990, “Development of Pharmaceuticals,” Vol. 7, Molecular Design, pp. 163 to 198. ) It may change to (10).
- the prodrugs of compounds (9) and (10) may be themselves or pharmacologically acceptable salts.
- salts include inorganic bases (eg, alkali metals such as sodium and potassium, calcium, magnesium, etc.) when the prodrugs of compounds (9) and (10) have an acidic group such as lipoxyl.
- organic amines such as N, N, -dibenzylethylenediamine, and basic amino acids such as arginine, lysine, and ordinine.
- the prodrug of the compound (9) or (10) has a basic group such as an amino group, an inorganic acid or an organic acid (eg, hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, carbonic acid, bicarbonate, formic acid, acetic acid, Propionic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.), aspartic acid, glutamic acid, etc. And a salt with an acidic amino acid.
- an inorganic acid or an organic acid eg, hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, carbonic acid, bicarbonate, formic acid, acetic acid, Propionic acid, trifluoroacetic acid, fumaric acid, ox
- the prodrugs of the compounds (9) and (10) may be either hydrates or non-hydrates.
- Compounds (9) and (10) may have one or two geometric isomers (cis-trans isomers) in the molecule, but compounds having cis- and trans-isomers in any ratio are also described in the present invention. Is included.
- Compound (10) has one or more Although the compound may have asymmetric carbon, both of the R configuration and the S configuration regarding these asymmetric carbons are included in the present invention.
- Compounds (9) and (10) may be labeled with an isotope (eg, 3 H, 14 C).
- polysaccharides eg, dextran, pullulan, manna, chitin, chitosan, etc.
- amino, carboxyl, and hydroxyl groups of compounds (9) and (10) It may be combined as a point.
- a complex in which the compounds (9) and (10) are included in cyclodextrin (these include a parabody, a / 3 body, and a ⁇ body, preferably a j3 body or a ⁇ ⁇ ⁇ body) may be used.
- Dulbecco's Modif ied Eagle Medium (hereinafter referred to as Dulbecco's Modif ied Eagle Medium
- DMEM fetal calf serum
- knockout serum replacement KSR (manufactured by Invitrogen)
- IraM J3 mercaptoethanol
- IX Non-essential amino acid stock I nv itrogen 11140-050
- 2raM L-Glutamine Invitrogen 25030-081
- 103 unit / ml ESGR0 CHEMIC0N International Inc., manufactured.
- ESGR0 contains mouse LIF as an active ingredient.
- ES cell differentiation inhibitor As a medium for assay, an Atsey medium was prepared by removing ESGR0 from the above ES cell medium.
- mice embryonic stem cell line D3 ES cells (Rolf Kemler, Max Planck Institut fur Immunbiologie Stuneweg5 D-79108Freiburg available from Germany lambda) was inoculated on one layer of a 6 cm diameter fibroblast feeder, and grown in 5 ml of ES medium by culturing for 2 days at 37 ° C. in a 5% CO 2 incubator.
- the supernatant was removed, the cells were resuspended in 2 Om1 of fresh ES cell medium, seeded on a 15 cm diameter cell culture dish pre-coated with 0.1% gelatin solution and incubated at 37 ° C. Incubated for 20 minutes. Twenty minutes later, the medium containing the suspended cells is collected with a pit, and seeded again on a 15 cm diameter cell culture dish coated with a 0.1% aqueous gelatin solution, at 37 ° C for 20 minutes. Incubated.
- the culture medium was transferred to a 50-ml sterile tube, centrifuged at 1,000 rpm for about 5 minutes using a tabletop centrifuge, the supernatant was removed, and the cells were re-suspended in 5 ml of ES cell medium to obtain ES cells.
- D3 ES cells obtained in the above (3) Preparation of mouse ES cells were placed in a 96-well cell culture dish (FALCON Cat. No. 3072, USA) previously coated with a 0.1% gelatin solution. 3 ⁇ 10 2 to 1 ⁇ 10 3 cells per well were seeded so that the ES cell culture medium per well was 90 ⁇ 1.
- Differentiation inhibitor (A, B, C, D, E, F) of the present invention dissolved in dimethyl sulfoxide (DMS0) or water or a mixture thereof so that each well has 0.4 to 40 ⁇ ⁇ / ⁇ 1.
- DMS0 dimethyl sulfoxide
- E to F is purchased from PHARMEKS Inc.
- ESGR0 10 1 ⁇ Ka ⁇ , at 37, were cultured in 5% C0 2 incubator for 7 days. DMS0 was brought into the medium at a final concentration of 0.1% or less. Only DMS0 was added to the control wells to a final concentration of 0.1%.
- the structure of compound A is shown in FIG. 1, and the structures of compounds BF are shown in FIG.
- P-NITR0PHENYLPH0SPHATE SOLUTION produced by MOSS Inc., PRODUCTNO. NPPD-1000, USA, or SIGMA, A-3469, USA) (hereinafter, p-NPP) And quantified.
- the medium is aspirated from each well of ES cells cultured for 7 days by the method described in the above (4) ES cell inhibitor, Atsusei 1, and the cells are washed with 100 / xl phosphate buffered saline. After washing once with (PBS), P- ⁇ l was added to each well and left at room temperature for 10 minutes. The reaction was stopped by adding 12.5 ⁇ l of 8 ⁇ sodium hydroxide solution to each well. The absorbance at 405 nm (0. D. 405) and the absorbance at 690 nm (0. D. 690) of the solution were measured with an absorbance meter (Molecular Devices, model: SPECTRA MAX190). .690 The value calculated in step was defined as the alkaline phosphatase activity. Figure 3 shows the results of the quantification as a rough sketch.
- the differentiation inhibitors of the present invention Compounds A to F, significantly amplified alkaline phosphatase activity as compared with the control DMS0 (0.1%). That is, it can be seen that the differentiation inhibitor of the present invention supported the culture of undifferentiated ES cells.
- ES cells were stained using alkaline phosphatase kit (SIGMADiagnostic Cat. No. 86-R).
- the medium is removed by suction from each cell of the ES cells cultured by the method described in (4) ES cell differentiation inhibition assay 1 above, and the cells are washed once with 2 ml of phosphate buffered saline (PBS). Thereafter, 2 ml of a cell fixing solution (25 ml of a formic acid solution (Cat. No. 91-5 manufactured by SIGMA), 65 ml of acetone, 8 ml of 37% formaldehyde) are added to each well, and the mixture is left to stand at room temperature for 30 seconds.
- a cell fixing solution 25 ml of a formic acid solution (Cat. No. 91-5 manufactured by SIGMA)
- 65 ml of acetone 8 ml of 37% formaldehyde
- ES cells cultured in the absence of ESGR0 as a negative control ES cells cultured in the presence of ESGRO (1000 units / ml) as a positive control, and the differentiation inhibitor of the present invention.
- ESGRO 1000 units / ml
- the ES cells cultured in the presence of Compound B were stained significantly deeper than the ES cells cultured in the absence of ESGR0, indicating that they had high alkaline phosphatase activity. Furthermore, the differentiation inhibitor of the present invention was also able to form undifferentiated colonies equivalent to ES cells cultured in the presence of the positive control ESGR0. That is, it can be seen that the differentiation inhibitor of the present invention strongly supported the proliferation of ES cells in an undifferentiated state. Compounds A and CF were stained in the same manner as compound B.
- LipofectAMINE 2000 manufactured by Invitrogen, USA
- a differentiation inhibitor dissolved in dimethyl sulfoxide (DMS0) or water or a mixture thereof to give a concentration of 0.4 to 40 ⁇ g / ml in each well, or 10 to: L000 units / ml
- 50 1 of ESGR0 diluted with ES Atsushi medium was added thereto, and the cells were cultured at 37 ° C. in a 5% CO 2 incubator for 6 to 24 hours.
- the luminescence signal of each cell was measured by the luciferase 'reporter enzyme using Pitka Gene Dual Chip Pansy (Toyo Ink Mfg., Japan) according to the attached protocol.
- ESGR0 enhanced the expression of the reporter enzyme by PSTAT3-TA-Luc in a dose-dependent manner, whereas the compound B of the present invention did not induce the expression of the reporter enzyme.
- Example 2 (1) ES cell differentiation inhibition assay 2
- D3 ES cells prepared according to the method described in (3) Preparation of mouse ES cells in Example 1 were transferred to a cell culture dish of 1 Ocm in diameter previously coated with a 0.1% aqueous gelatin solution to obtain 8 ⁇ 10 4 cells. Then, the cells were seeded so that the ES cell medium was 10 ml. To each dish, the differentiation inhibitor (A to F) of the present invention dissolved in dimethyl sulfoxide (DMS0), a medium, or a mixture thereof, so as to have a concentration of 40 ⁇ g / ml, or 10 4 units / ml. the prepared ESGRO added 1 ml, and cultured for 7 days at 37 ° C, 5% C0 2 Inkyube one coater. DMS0 was brought into the medium at a final concentration of 0.1% or less.
- DMS0 dimethyl sulfoxide
- the LightCycler First Start DNA Master SYBR Green I Kit (Roche's Diagnostics, Inc.) PCR was performed according to the attached protocol.
- the expression levels of the Oct-3 / 4 gene and the glycemic aldehyde triphosphate dehydrogenase (GAPDH) gene as an internal standard were measured.
- the sense primer 0CT3 up (SEQ ID NO: 1)
- the antisense primer 0ct3 down SEQ ID NO: 2
- the sense primer GAPDH was used.
- up (SEQ ID NO: 3) and antisense primer GAPDH down (SEQ ID NO: 4) were used.
- the composition of the PCR reaction solution and the reaction conditions are shown below.
- D.3 ES cells prepared according to the method described in (3) Preparation of mouse ES cells in Example 1 were placed on a 10 cm diameter cell culture dish previously coated with a 0.1% aqueous gelatin solution, and 7.85 ⁇ 10 5 cells were placed in the dish. Then, the cells were seeded so that the ES cell medium was 10 ml.
- the differentiation inhibiting agent B of the present invention at a final concentration of 4 [mu] g / ml, or in addition to the medium ESGR0 a final concentration lX10 3 unit / ml, 37 ° C, 5% C0 2 Inkyubeta one 1 Cultured for one day.
- RNA solution After removing the supernatant, 1 ml of a 70% aqueous ethanol solution was added, shaken, and centrifuged at 10,000 rpm in a microcentrifuge at 4 ° C for about 5 minutes. After removing the supernatant and drying the precipitate, the precipitate was dissolved in 30 ⁇ l of distilled water to obtain a total RNA solution.
- RNA obtained in this manner was converted into type ⁇ , Deoxyribobonucleasasel, AmplificcationGrade) (manufactured by Invitrogen), Superscript III First-Strand Synthesis System for RT-PCR.
- cDNA was synthesized according to the attached protocol. That is, add 1 ⁇ l l O XDNa sel Reaction Buffer and 1 / zl l O XD Na sel Buffer (from Invitrogen) to 2 / Z g of total RNA, and add 10 ⁇ l of distilled water. A reaction mixture was prepared and incubated at room temperature for 10 minutes.
- the cells were incubated at 85 ° C for 5 minutes and then placed on ice for 1 minute.
- One ⁇ l of RNase H was added, and the mixture was incubated at 37 ° C for 20 minutes to obtain cDNA.
- a part of the synthesized cDNA obtained in this way was diluted 5-fold with distilled water, and the 21 was used as type II, and LightCycler First Start DNA Master SYBR Green I Kit (Roche Diagnostics) PCR was performed according to the attached protocol. Na nog gene and glyceraldehyde triphosphate dehydrogenase as internal standard
- GAPDH The expression level of the gene was measured.
- Lima ⁇ "Na nog— up (SEQ ID NO: 5) and antisense primer N anog— down (SEQ ID NO: 6) were used to amplify the GAPDH gene using the sense primer GAPDH up (SEQ ID NO: 3).
- antisense primer GAPDH down SEQ ID NO: 4 in the Sequence Listing
- the expression level of the Nanog gene of the ES cells cultured in the presence of the differentiation inhibitor B of the present invention was determined by the ES cells cultured in a medium containing no differentiation inhibitor and a medium containing 1,000 000 units of Zm1. (Fig. 7). That is, it was confirmed from the expression level of the Nanog gene that the differentiation inhibitor B of the present invention had an effect of maintaining undifferentiation of ES cells.
- the expression level of the Nanog gene was increased. That is, it was revealed that the cells have an activity of maintaining undifferentiation of ES cells.
- ES cell differentiation inhibition assay 2 The cells cultured in (1) ES cell differentiation inhibition assay 2 were washed twice with PBS, and the cells were detached from the dish with a cell scraper. 300 ⁇ l of Hanks balanced salt solution (HBSS, manufactured by Invitrogen) containing 2% FBS was added so that the number of cells became 6 ⁇ 10 5 . 30 ⁇ l of MX-SSEA-1 antibody (manufactured by Kyowa Medex) diluted 50-fold with HBSS was added, and the mixture was allowed to stand on ice for 40 minutes.
- HBSS Hanks balanced salt solution
- MX-SSEA-1 antibody manufactured by Kyowa Medex
- the flow cytometer used was a FACSCalibur (BECT0N DICKINSON) and the measurement condition data collection and analysis software was CELLQuest (BECT0N DICKINSON).
- the results are shown in FIG.
- the average fluorescence intensity per cell of cells cultured with the addition of each differentiation inhibitor, that is, the intensity of SSEA-1 antigen expression per cell, is higher than that of cells cultured in a medium without differentiation inhibitors. It was significantly increased. Similar experiments with Compounds A, C, and E also showed significantly higher levels of SSEA-1 expression. That is, the differentiation inhibitor of the present invention is an undifferentiated ES Example 3 shows that cells are maintained
- a D3 ES cell prepared according to the method described in (3) Preparation of mouse ES cell in Example 1 was coated with a 96-well cell culture dish (FALCON Cat. No. 3072, USA), 3200 cells per well were seeded at 100 1 ES cell Atsell medium per well.
- the differentiation inhibitor of the present invention (a to o: a, j to 10) dissolved in dimethyl sulfoxide (DMS0) or water or a mixture thereof so as to have a concentration of 0.4 to 40 ⁇ g / ml in each well.
- m is IF LAB Ltd., Ukraine, b, c, f, n is PHARMEKS, Russia, d, e, o is SPECS, Netherlands, g-i is CH EMB RIDGE, purchased from the United States), or ESGRO was added and cultured in a 5% CO 2 incubator at 37 ° C for 4 days.
- DMS0 was brought into the medium at a final concentration of 0.1% or less. Only DMS0 was added to the control wells to a final concentration of 0.1%.
- Fig. 9 shows the structures of the differentiation inhibitors a to o.
- the al cell phosphatase activity of ES cells was measured using p-NITR0PHENYLPH0SPHATE SOLUTION (MOSS Inc., PRODUCTNO. NPPD-1000, USA, or SIGMA, A-3469, USA) (hereinafter, p-PP). And quantified.
- the medium is aspirated off from each well of ES cells cultured for 4 days by the method described in (1) ES cell differentiation inhibition assay 4 above, and the cells are washed with 100 ⁇ l of phosphate buffered saline (PBS). After washing once, ⁇ - ⁇ 1 was added to each well, and the plate was allowed to stand at room temperature for 10 minutes.
- PBS phosphate buffered saline
- FIG. 10 shows a graph of the quantification result.
- the differentiation inhibitors of the present invention compounds a to o, significantly amplified the activity of lipophilic phosphatase as compared with DMSO (0.1%) as a control. That is, the differentiation inhibitor of the present invention supported the culture of undifferentiated ES cells.
- the D 3 ES cells prepared according to the method described in (3) Preparation of mouse ES cells in Example 1 were previously purified by 0.1 ° /. 8 ⁇ 10 4 cells were seeded on a cell culture dish of 1 Ocm in diameter coated with a gelatin aqueous solution of the above so that the ES cell Atssay medium was 10 ml.
- To each dish add 1 ml of ESGR0 to 40 ⁇ / ⁇ 1 in dimethyl sulfoxide (DMS0) or a differentiation inhibitor of the present invention (a to o) dissolved in a medium or a mixture thereof. ° and cultured for 4 days at C, 5% C0 2 incubator. DMS0 was brought into the medium at a final concentration of 0.1% or less.
- DMS0 dimethyl sulfoxide
- the cells cultured in the above (3) ES cell differentiation inhibition assay 5 were washed twice with PBS, and the cells were detached from the dish with a cell scraper.
- 300 1 Hanks balanced salt solution (HBSS, manufactured by Invitrogen) containing 2% FBS was prepared so that the number of cells became 6 ⁇ 10 5 cells.
- HBSS Hanks balanced salt solution
- MX-SSEA-1 antibody manufactured by Kyowa Medex
- Flow cytometer is FACSCalibur (BECT0N DICKINSON, US Country) and the measurement condition data collection and analysis software used was CELLQuest (BECTON DICKINSON, USA).
- the results are shown in FIG.
- a similar experiment was performed for compounds b to o, and it was also shown that the expression level of SSEA-1 was significantly higher. That is, it became clear that the differentiation inhibitor of the present invention maintains undifferentiated ES cells.
- D3 ES cells prepared according to the method described in (3) Preparation of ES cells in Example 1 were coated with a 24-well cell culture dish (FALCON Cat. No. 3047, USA) previously coated with a 0.1% aqueous gelatin solution. ) in a 1 X 1 0 5 cells per Ueru, ES cell medium per Ueru is seeded so that the 500 1, 37, in 5% C0 2 incubator and cultured for 12 hours to 24 hours. Next, using LipofectAMINE 2000 (manufactured by Invitrogen, USA) according to the attached protocol, PSTAT3-TA-Luc or pTA-Luc vector (manufactured by C1ontech, USA) was added at 0.9 / well.
- LipofectAMINE 2000 manufactured by Invitrogen, USA
- PSTAT3-TA-Luc or pTA-Luc vector manufactured by C1ontech, USA
- zg was transfected into ES cells.
- pRL-TK vector Promega, USA
- pRL-TK vector Promega, USA
- the medium was aspirated, After washing twice with PBS, and added ES Atsusi medium by each Ueru 500 1.
- a differentiation inhibitor dissolved in dimethyl sulfoxide (DMS0) or water or a mixture thereof at a concentration of 0.4 to 40 ⁇ g / ml, or an ES at a concentration of 10 to 10,000 units / ml in each well. and cultured for 6 to 24 hours at ESGR0 diluted with Assi medium 50 ⁇ 1 ⁇ Ka ⁇ to 37 ° C, 5% C0 2 Inkyu activator.
- DMS0 dimethyl sulfoxide
- Example 4 Subculture of ES cells
- ES cells prepared according to the method described in (3) Preparation of mouse ES cells in Example 1 were placed in a cell culture dish of 6 cm in diameter previously coated with a 0.1% aqueous gelatin solution at 3 ⁇ 10 5 cells. Were seeded so that the ES cell medium was 4.5 ml. Jimechirusurufu Okishido so that 10 ⁇ 40 ⁇ g / m 1 to each dish (DMSO), or medium, or differentiation inhibiting agent of the present invention dissolved in the mixture (to F, to o), or 10 4 units / m 1 of ESGRO was added with 0.5 ml of mash. DMSO was brought into the medium at a final concentration of 0.1% or less.
- a control containing only DMSO 0.5 ml of a 1% concentration solution diluted with a medium was added to a final concentration of 0.1%.
- the cells were cultured in a 5% CO 2 incubator at 37 ° C. for 7 to 30 days.
- the medium was changed every day, and the culture medium was changed every 2 to 3 days so as to obtain 3 ⁇ 10 5 cells / dish.
- Al cell phosphatase activity of ES cells cultured for 7 days or 30 days using the differentiation inhibitor of the present invention was quantified by colony assay. That is, ES cells subcultured by the above method were placed in a 96-well cell culture dish (FALCON Cat. No. 3072, USA) previously coated with a 0.1% aqueous gelatin solution at 1 ⁇ 10 3 cells / liter. Individual cells were inoculated so that the ES cell culture medium per cell was 90 ⁇ l per well. To each well, ESG RO diluted with a medium so as to have a concentration of 0 to 10 3 units / m 1 was added with 10 ⁇ l of mash, and cultured at 37 ° C. in a 5% CO 2 incubator for 4 days.
- FIG. 13 shows the results of quantitative determination of the enzyme lipophosphatase of ES cells subcultured with compound B for 30 days and ES cells subcultured for 7 days in serum-free medium with compound f.
- FIG. 14 shows the results of the quantitative determination of the lipophilic phosphatase.
- ES cells subcultured with the differentiation inhibitor of the present invention Compounds B and ⁇ , significantly amplified the activity of lipophilic phosphatase as compared to ES cells cultured with DMS ⁇ (0.1%). That is, it can be seen that the differentiation inhibitor of the present invention supported the undifferentiated state of ES cells even in long-term culture.
- DME / F-12, 1: 1 (SI GM AD6421) was added with factors at the following final concentrations to prepare a culture medium for cynomolgus monkey ES cells.
- KSR 10828-028 manufactured by InVitrogen
- IX non-essential amino acid SI GMA M 7145
- 2 mM L—G 1 utamine SI GMA G7513
- 1 mM sodium pyruvate SI GMA S 8636
- IX penicillin / streptomycin solution SI GMA P 078 l
- DMEM manufactured by Invitrogen 1 was used as a culture medium for one mouse feeder cell for cultivating monkey ES cells. In 1960-044), each factor was added at the final concentrations shown below to prepare.
- Kuizaru ES cells manufactured by Tanabe pharmaceutical Co., Ltd.
- the cells were grown for three days in a 5% CO 2 incubator at 37 ° C. in a quinary ES cell culture medium.
- GFR Growth Factor Reduced
- BD Matrigel Nippon Becton, Dateskinson, 354230, Japan
- BD Matrigel Matrix Nippon Becton Thaton's Dickinson's 354234
- the differentiation inhibitor of the present invention (A to F, a to o) dissolved in dimethyl sulfoxide (DMSO) or a medium or a mixture thereof so that each dish has a concentration of 8 to 40 ⁇ g / m 1.
- DMSO dimethyl sulfoxide
- a medium or a mixture thereof so that each dish has a concentration of 8 to 40 ⁇ g / m 1.
- 0.5-ml of 6-bromoindirubin-3 oxime. C, and cultured in a 5% CO 2 incubator.
- the cells were passaged every 2 to 4 days according to the method described in (2) Preparation of Power-Supplied Monkey ES Cells.
- DM SO was brought into the medium at a final concentration of 0.1% or less.
- the above cultured cells were evaluated by staining for alkaline phosphatase described in Example 1 above.
- Fig. 15 shows the results of staining with alkaline phosphatase of cells cultured for 2 days after addition of compound B or compound f as the ratio of the number of stained colonies to the total number of colonies. Under or in the presence of compound f, the cells were cultured for 3 days and subcultured. The photograph of alkaline phosphatase staining after 3 days is shown in FIG.
- Chinese cynomolgus monkey ES cells subcultured in the presence of compound f are the Chinese cynomolgus monkey ES cells subcultured in the presence of DMS0. Staining was significantly higher than that of.
- m-Aminoacetophenone (Aldrich, USA) is dissolved in benzene, hydrochloric acid gas is passed through, the resulting precipitate is filtered off and recrystallized from isopropanol.
- p-aminoacetophenone hydrochloride Dissolve the obtained P-aminoacetophenone hydrochloride in a 20% aqueous ethanol solution and acidify with concentrated hydrochloric acid in an ice bath. An aqueous solution of sodium nitrite is added dropwise and treated with urea to obtain a diazonium salt solution.
- the D3 ES cells cultured using the method described in (2) Culture of mouse ES cells in Example 1 are washed twice with PBS. A 0.25% trypsin solution (manufactured by InV Itrogen) was added, and the mixture was incubated at 37 ° C for 5 minutes to remove colonies of undifferentiated D3ES cells from the feeder. 5 ml of ES cell culture medium was added, cell colonies were dispersed using a small-diameter pipette, transferred to a 15-ml sterile tube, and pelletized by centrifugation at 800 rpm for about 5 minutes in a tabletop centrifuge (Tomy Seie). .
- ES cells were stained with alkaline phosphatase kit (SIGMADiagnostic Cat. No. 86-R).
- the medium is aspirated from each well of the ES cells cultured by the method described in the above “ES cell differentiation inhibition assay”, and the cells are washed once with 0.5 ml of phosphate buffered saline (PBS). Thereafter, 0.5 ml of a cell fixative (25 ml citric acid solution (SIGMA Cat. No. 91-5), 65 ml acetone, 8 ml 37% formaldehyde) is added to each well, and the mixture is allowed to stand at room temperature for 30 seconds.
- a cell fixative 25 ml citric acid solution (SIGMA Cat. No. 91-5)
- 65 ml acetone, 8 ml 37% formaldehyde is added to each well, and the mixture is allowed to stand at room temperature for 30 seconds.
- ES cells cultured in the absence of the negative control, ESGR0, in the presence of the positive control, ESGR0 (1000 units / ml) In cultured ES cells, and it was compared stained images of the compound 4 (4 ⁇ ⁇ / ⁇ 1) ES cells cultured in the presence of the present invention (see FIG. 19).
- the ES cells cultured in the presence of Compound II were stained significantly deeper than the ES cells cultured in the absence of ESGR0, indicating that they had high alkaline phosphatase activity.
- the compound of the present invention was also able to form undifferentiated colonies equivalent to ES cells cultured in the presence of the positive control ESGR0. That is, it can be seen that the compound of the present invention strongly supported the proliferation of ES cells in an undifferentiated state.
- stem cells preferably embryonic stem cells
- the differentiation inhibitor provided by the present invention, a culture method using the same, and a culture solution can be applied to produce a stem cell, preferably an embryonic stem cell, as a cell source used for cell transplantation.
- the differentiation inhibitor provided by the present invention, and the culture method using the same can be used to reduce one or many genetic modifications. It can be applied to produce embryonic stem cells. Examples of such applications include, but are not limited to, the development of cell-based models of the disease, as well as the development of tissues specific for transplantation to treat genetic diseases.
- the dehydration inhibitor or bicyclic compound of the present invention can proliferate stem cells in an undivided state, and as a result, cultured cells and tissues can be suitably used in the field of regenerative medicine. Available.
- the present invention can be applied to a pharmaceutical composition.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020057024980A KR101160698B1 (ko) | 2003-06-27 | 2004-06-25 | 세포 분화 억제제, 이것을 이용하는 세포 배양 방법, 배양 배지 및 배양된 세포주 |
EP04746848A EP1640449A4 (en) | 2003-06-27 | 2004-06-25 | CELL DIFFERENTIATION INHIBITOR AGENT, CELL CULTURE METHOD USING THE SAME, CULTURE MEDIUM AND CULTIVATED CELL LINE |
JP2005511810A JP4667241B2 (ja) | 2003-06-27 | 2004-06-25 | 細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株 |
AU2004257966A AU2004257966B2 (en) | 2003-06-27 | 2004-06-25 | Cell diffrentiation inhibitor, cell culture method using the same, liquid culture medium and cultured cell line |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-185398 | 2003-06-27 | ||
JP2003185398 | 2003-06-27 | ||
JP2003-353870 | 2003-10-14 | ||
JP2003353870 | 2003-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005007838A1 true WO2005007838A1 (ja) | 2005-01-27 |
Family
ID=34082299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/009379 WO2005007838A1 (ja) | 2003-06-27 | 2004-06-25 | 細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20050153941A1 (ja) |
EP (1) | EP1640449A4 (ja) |
JP (1) | JP4667241B2 (ja) |
KR (1) | KR101160698B1 (ja) |
AU (1) | AU2004257966B2 (ja) |
WO (1) | WO2005007838A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006204292A (ja) * | 2004-12-27 | 2006-08-10 | Asahi Kasei Corp | ヒト胚性幹細胞分化抑制剤 |
JP2008195642A (ja) * | 2007-02-13 | 2008-08-28 | Asahi Kasei Corp | インドール誘導体 |
US9435493B2 (en) | 2009-10-27 | 2016-09-06 | Cree, Inc. | Hybrid reflector system for lighting device |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2524922T3 (es) | 2005-05-10 | 2014-12-15 | Intermune, Inc. | Derivados de piridona para modular el sistema de proteína cinasa activada por estrés |
KR20080073774A (ko) * | 2005-11-28 | 2008-08-11 | 주식회사 중외제약 | 배양에서 세포의 무혈청 증식 |
GB0704407D0 (en) * | 2007-03-07 | 2007-04-18 | Glaxo Group Ltd | Compounds |
CA3034994A1 (en) | 2008-06-03 | 2009-12-10 | Intermune, Inc. | Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders |
KR101812820B1 (ko) * | 2010-01-08 | 2017-12-27 | 웨이크 포리스트 유니버시티 헬스 사이언시즈 | 전달 시스템 |
EP2683328B1 (en) | 2011-03-07 | 2017-11-08 | Wake Forest University Health Sciences | Delivery system |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2015194710A1 (ko) * | 2014-06-17 | 2015-12-23 | 가톨릭대학교 산학협력단 | Stat3 억제제가 처리된 간엽줄기세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
KR101705412B1 (ko) * | 2014-06-17 | 2017-02-09 | 가톨릭대학교 산학협력단 | Stat3 억제제가 처리된 간엽줄기세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
US10006005B2 (en) * | 2014-06-27 | 2018-06-26 | National University Corporation Chiba University | Culture medium and method for inducing differentiation of pluripotent stem cells to hepatoblasts |
KR102648947B1 (ko) | 2017-04-26 | 2024-03-18 | 바실리어 파마슈티카 인터내셔널 리미티드 | 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정 |
JP2023543895A (ja) * | 2020-09-30 | 2023-10-18 | エフエル2022-001, インコーポレイテッド | Hsd17b13阻害剤及びその使用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07100685B2 (ja) * | 1985-08-02 | 1995-11-01 | レオ・ファ−マシュ−ティカル・プロダクツ・リミテッド・エイ/エス(レ−ベンス・ケミスケ・ファブリック・プロデュクチオンスアクチ−セルスカブ) | 新規ビタミンd類似体 |
US4667083A (en) * | 1986-02-14 | 1987-05-19 | Westinghouse Electric Corp. | Torch for preheating a continuously fed welding wire |
WO1999020741A1 (en) | 1997-10-23 | 1999-04-29 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
AU2002249913A1 (en) * | 2001-01-03 | 2002-08-12 | President And Fellows Of Harvard College | Compounds regulating cell proliferation and differentiation |
US20030082810A1 (en) * | 2001-02-26 | 2003-05-01 | Palle Serup | Methods for generating insulin-secreting cells suitable for transplantation |
WO2003010303A1 (en) * | 2001-07-24 | 2003-02-06 | Es Cell International Pte Ltd | Methods of inducing differentiation of stem cells |
ATE538785T1 (de) * | 2001-07-31 | 2012-01-15 | Genzyme Global S A R L | Verfahren zur mobilisierung von vorläufer/stammzellen |
JP4148897B2 (ja) | 2001-10-31 | 2008-09-10 | 旭化成株式会社 | 胚性幹細胞培養用基材および培養方法 |
AUPS209402A0 (en) | 2002-05-02 | 2002-06-06 | Victor Chang Cardiac Research Institute, The | Cell differentiation and self renewal |
CN1668733A (zh) * | 2002-05-30 | 2005-09-14 | 细胞基因公司 | 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法 |
EP1511838A4 (en) | 2002-06-07 | 2007-01-10 | Es Cell Int Pte Ltd | METHOD FOR CONTROLLING DIFFERENTIATION IN STEM CELLS |
WO2005038010A2 (en) * | 2003-10-16 | 2005-04-28 | The University Court Of The University Of Edinburgh | Control of es cell self-renewal and lineage specification, and medium therefor |
WO2005085422A1 (en) * | 2004-02-27 | 2005-09-15 | Michigan State University | Adult stem cells and uses thereof |
US7662941B2 (en) * | 2005-01-18 | 2010-02-16 | The Trustees of the University of Princeton - Princeton University | Embryonic stem cell self maintenance and renewal reporter |
WO2008089351A1 (en) * | 2007-01-17 | 2008-07-24 | Wisconsin Alumni Research Foundation | Improved culture of stem cells |
-
2004
- 2004-06-25 WO PCT/JP2004/009379 patent/WO2005007838A1/ja active Application Filing
- 2004-06-25 EP EP04746848A patent/EP1640449A4/en not_active Withdrawn
- 2004-06-25 AU AU2004257966A patent/AU2004257966B2/en not_active Expired
- 2004-06-25 US US10/875,194 patent/US20050153941A1/en not_active Abandoned
- 2004-06-25 JP JP2005511810A patent/JP4667241B2/ja not_active Expired - Lifetime
- 2004-06-25 KR KR1020057024980A patent/KR101160698B1/ko active IP Right Grant
-
2008
- 2008-09-18 US US12/233,252 patent/US8883504B2/en active Active
Non-Patent Citations (1)
Title |
---|
ATANES N. ET AL: "The reaction of 1-Alkyldihydroisoquinolines with benzyne. An unexpected entry to dibenzindolizines", TETRAHEDRON LETTERS, vol. 28, no. 7, 1987, pages 817 - 820, XP002981846 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006204292A (ja) * | 2004-12-27 | 2006-08-10 | Asahi Kasei Corp | ヒト胚性幹細胞分化抑制剤 |
JP2008195642A (ja) * | 2007-02-13 | 2008-08-28 | Asahi Kasei Corp | インドール誘導体 |
US9435493B2 (en) | 2009-10-27 | 2016-09-06 | Cree, Inc. | Hybrid reflector system for lighting device |
Also Published As
Publication number | Publication date |
---|---|
JP4667241B2 (ja) | 2011-04-06 |
JPWO2005007838A1 (ja) | 2006-08-31 |
US20050153941A1 (en) | 2005-07-14 |
AU2004257966A1 (en) | 2005-01-27 |
EP1640449A4 (en) | 2009-03-25 |
US20090155906A1 (en) | 2009-06-18 |
KR101160698B1 (ko) | 2012-06-28 |
KR20060056901A (ko) | 2006-05-25 |
AU2004257966B2 (en) | 2008-10-02 |
US8883504B2 (en) | 2014-11-11 |
EP1640449A1 (en) | 2006-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8883504B2 (en) | Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line | |
CN104508121B (zh) | 体外诱导多能干细胞分化为心室肌细胞的方法 | |
US7452718B2 (en) | Direct differentiation method for making cardiomyocytes from human embryonic stem cells | |
JP7029144B2 (ja) | 腺性下垂体又はその前駆組織の製造方法 | |
EP2268795B1 (en) | Method for generating primate cardiovascular progenitor cells for clinical use from primate embryonic stem cells or embryonic-like state cells, and their applications | |
US20080254003A1 (en) | Differentiation of Human Embryonic Stem Cells and Cardiomyocytes and Cardiomyocyte Progenitors Derived Therefrom | |
JP5764598B2 (ja) | 幹細胞を培養するための方法及びキット | |
IL190016A (en) | Cardiomyocyte production | |
WO2009116893A1 (ru) | Способ получения эндотелиальных клеток (варианты) | |
JP5107589B2 (ja) | インドール誘導体 | |
JP2006204292A (ja) | ヒト胚性幹細胞分化抑制剤 | |
H Parsons et al. | Patents on technologies of human tissue and organ regeneration from pluripotent human embryonic stem cells | |
KR20090090586A (ko) | 배아줄기세포를 심근세포로 분화 유도하는 방법 | |
Klimanskaya | Retinal pigment epithelium | |
WO2012157612A1 (ja) | 細胞分化誘導剤および分化誘導方法 | |
US20200308548A1 (en) | Amplifying Beta Cell Differentiation with Small Molecules BET (Bromodomain And Extraterminal Family Of Bromodomain-Containing Proteins) Inhibitors | |
JP2005013152A (ja) | 細胞分化抑制剤及びこれを用いた細胞培養方法、培養液、培養された細胞 | |
GB2419890A (en) | Characterization and isolation of subsets of human embryonic stem cells (HES) | |
JP4406601B2 (ja) | 組織幹細胞増殖剤 | |
JP2011152111A (ja) | 多能性幹細胞培養用培地 | |
IL178006A (en) | Method for making high purity cardiomyocyte preparations suitable for regenerative medicine | |
KR20090059339A (ko) | 줄기세포에서 심장근육세포로의 분화를 촉진하는 화합물및 그 유도체 | |
JP2005000034A (ja) | 全能性幹細胞培養用フィーダー | |
AU2005318931A1 (en) | Differentiation of human embryonic stem cells and cardiomyocytes and cardiomyocyte progenitors derived therefrom | |
Shafa et al. | Stirred Suspension Bioreactor Suppresses ESC Differentiation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005511810 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057024980 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004746848 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004257966 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004257966 Country of ref document: AU Date of ref document: 20040625 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004746848 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057024980 Country of ref document: KR |